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Abstract 
Optical Assessment of Vascular Disease Progression and Treatment 
Joshua A. Samuels 
Peter A. Lewin, Ph.D. 
 
 
Vascular disease manifests itself in many different forms, including chronic ulcers which 
do not heal, impaired blood flow to the limbs, or damage to the natural reperfusion 
process.  The current forms of assessing vascular disease are often subjective and provide 
incomplete knowledge about the tissue of interest.  This work focused on developing 
non-invasive techniques to quantitatively evaluate three specific elements of vascular 
disease: diabetic ulcers, venous ulcers, and peripheral arterial disease.  Diffuse Near 
Infrared Spectroscopy (DNIRS) was used to predict healing (82% positive predictive 
value) in diabetic ulcers after 4 weeks of assessment (sensitivity of 0.9 and specificity of 
0.86; p<0.002), proving to be an alternative and superior method to wound size reduction 
alone (the current gold standard).  A novel therapeutic ultrasound treatment for venous 
ulcers, using a low-frequency (20kHz), low intensity (<100mW/cm2 ISPTP), fully-
wearable applicator,  was assessed using DNIRS and Diffuse Correlation Spectroscopy 
(DCS), wherein it was established that capillary flow changes over time in healing 
venous ulcers compared to wounds which do not heal (p<0.01).  It was also determined 
that the ultrasound therapy was successful at improving wound outcomes, specifically the 
rate of wound closure per week (p<0.05 for wound size, p<0.01 for optical data).  Finally, 
xiii 
DNIRS and DCS were used in conjunction to assess the reactive hyperemic response in 
patients with suspected Peripheral Arterial Disease (PAD).  It was found that the time 
between the release of cuff occlusion in the diseased limb and the first peak of 
reperfusion (flow mediated dilatation) correlated to PAD severity, with longer times (>30 
seconds) belonging to patients with PAD (p<0.05).  Additionally, it was discovered that 
the magnitude of the reperfusion did not relate to PAD, but rather to tobacco use.  
Patients who smoked had reduced hyperemic responses (p<0.02), whether or not they had 
PAD.  Overall, this work represents an improvement over gold standard qualitative 
assessments of vascular health and the results obtained promise to develop new clinically 
relevant and quantitative techniques using non-invasive optical modalities. 
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Chapter 1: Introduction 
1.1 Problem Statement 
This research focuses on Chronic Venous Ulcerations (CVUs), Diabetic Foot 
Ulcerations (DFUs) and Peripheral Arterial Disease (PAD).  Vascular disease can take 
the form of a wide variety of common diseases, ranging from arterial blockages that lead 
to heart attacks, a deep vein thrombosis (DVT), which can dislodge and cause strokes, to 
venous insufficiency, leading to ulceration and potential amputation.  Chronic Venous 
Insufficiency (CVI) involves malfunctioning valves in the venous return system which 
lead to accumulations of a fluid called edema in the interstitial space along limbs [1].  
The severity of CVI is qualitatively assessed using the CEAP scale (standing for Clinical 
severity, Etiology, Anatomy, Pathophysiology) and ranges from superficial spider veins, 
presence of varicose veins, hyperpigmentation, and up to open venous ulcers.  Each year, 
500,000 Americans are treated for venous ulcers, costing the United States healthcare 
system between $2.5 and $3.5 billion [2-4]. As for diabetic foot ulcers, they account for 
nearly 75,000 cases per year[5] and result in $5 billion per year in direct costs[6].  Forty-
six percent of  hospitalizations for foot ulcers are attributable to diabetic 
complications[7].  Amputation rates for diabetic ulcers in the United states have been 
reported at 14%[5].  In comparison, studies have shown that the cost of treating a foot 
ulcer can range from $10,000 to $60,000[8-11].  Much of this cost stems from expensive 
wound care treatments, ranging from simple hydrogel dressings (~$50/week), to skin 
substitutes, to costly hyperbaric oxygen therapy (~$1,800/week).  The costs associated 
with treating chronic ulcers are exacerbated by the difficulty in quantitatively assessing 
(registering reduction in size by 40% in 4 weeks, as per wound healing guideline 4.5[12]) 
the state of the wound [13].  Surface area measurements using rulers are error-prone [14] 
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and have relatively poor positive predictive value (58-62%) for healing outcomes[13, 15].  
As there is a variety of therapy options for ulcers, both venous and diabetic[16], ranging 
from conservative wound management with compression and hydrogel dressings to 
expensive negative pressure therapy, hyperbaric oxygen therapy, and surgical skin 
grafting, knowing the healing progress of the wound is important when making the 
decision to continue or alter the treatment regimen.  One major focus of this work 
involved the use of optical technologies to quantify healing in chronic wounds to predict 
healing and provide additional quantitative assessment of wound healing to aid in 
physician's decisions regarding wound management. Furthermore, an analysis of 
potential cost savings using optical prediction methods was performed.  This work 
expands upon previous successful results obtained by the author’s research team using 
optical devices to assess the progress of healing diabetic ulcers by quantifying 
concentrations of oxygenated and deoxygenated hemoglobin in the wound bed over time 
[13, 17-19]. 
 In addition to chronic ulcers, this work examined another vascular disease, 
specifically Peripheral Arterial Disease.  Peripheral arterial disease (PAD) affects 10 
million Americans [20] and adds $4.4 billion to annual US healthcare costs [21].  The 
narrowing or blocking of arteries can cause pain in the legs (called intermittent 
claudication), lead to strokes, or result in complete loss of circulation in limbs causing 
gangrene and loss of limb [22].  The diagnostic testing for Peripheral Arterial Disease, 
which uses Doppler ultrasound to assess the flow of blood through arteries, involves limb 
compression during ultrasound examination, requiring trained professionals and often 
painful squeezing of limbs using customized compression cuffs. To complicate matters, 
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compression cannot be performed on a variety of people, including those with acute 
DVTs or with painful open ulcerations, therefore an effort to eliminate or minimize 
compression will be made when using optical methods to perform PAD severity 
assessment, as described below.   
 As all three diseases discussed (CVUs, DFUs, and PAD) are related to 
hemodynamics, it follows that innovative approaches to assess blood flow could be 
utilized for diagnostic and disease progression monitoring purposes.  Optical 
technologies are capable of performing hemodynamic measurements in small vessels and 
capillaries (5µm-1mm) at depths exceeding 1cm.  The advantages of these methods, 
described in greater detail in the following chapters, involve real-time, bedside 
measurements while avoiding the clinician’s subjectivity.   
 This thesis is organized in the following way.  First there is a definition of the 
overall objectives and specific aims.  Next there is an overview of vascular disease and 
wound healing.  Chapter 3 consists of a review of previous optical methodologies for 
assessing vascular disease.  Chapter 4 focuses on the background, design, and calibration 
of the Diffuse Correlation Spectroscopy system.  Chapter 5 describes a human study 
where DFUs were monitored with DNIRS to predict healing.  Chapter 6 describes 
another human study where CVUs were treated with low-frequency (20kHz), low 
intensity (<100mW/cm2 ISPTP, or spatial-peak, temporal-peak) ultrasound and assessed 
using DCS.  Chapter 7 describes a human study using DCS to assess PAD severity and 
the impact of smoking on capillary reperfusion.  Finally, Chapter 8 details the 
conclusions and proposed future work. 
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1.2 Objectives 
 The overall goal of this research was to develop a protocol for non-invasive 
assessment of vascular disease and ulcer healing using diffuse near infrared spectroscopy 
(DNIRS) and diffuse correlation spectroscopy (DCS). 
 The main hypothesis supporting this research was that changes in hemoglobin 
concentrations as well as capillary flow in the tissue correspond to healing or current 
vascular disease state and could be assessed in a non-invasive manner using optical 
systems. 
Accordingly, the aims of this research were: 
Specific Aim 1: Construction and calibration a hybrid Diffuse Near Infrared 
Spectroscopy and Diffuse Correlation Spectroscopy system to assess 
micro-vascular flow. 
Specific Aim 2: Assessment of healing in both diabetic and venous ulcers using the 
optical systems described in Aim 1 
Specific Aim 3: Development a protocol, using the combined system described in Aim 1, 
for assessing peripheral arterial disease severity to supplement 
information ascertained using segmental compression ultrasound 
method, the current gold standard diagnostic procedure for peripheral 
arterial disease.   
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Chapter 2: Overview of Vascular Disease 
 This chapter provides a brief summary of healthy and impaired circulation and 
how it leads to peripheral arterial disease and ulcer formation. As these are broad topics, 
when appropriate, references are provided to more comprehensive review papers or 
publications throughout the chapter. 
 At its most basic level, circulation is the systemic movement of blood to deliver 
oxygen to tissue and remove waste.  This requires specific sets of environmental factors, 
including pressure changes to allow oxygen delivery, valves to prevent backflow in veins, 
and arterial wall compliance, to ensure successful implementation.  Vascular diseases 
form when pathophysiologies impair normal function.  This section considers Arterial 
and Venous diseases separately. 
2.1Peripheral arterial disease 
 Peripheral Arterial Disease (PAD) refers to the obstruction of blood flow in the 
arteries (excluding the coronary and intracranial vessels, which are defined as separate 
diseases)[23]. Although PAD can include blockages in the upper extremities and carotids, 
the research presented herein focuses on lower extremity PAD, as it is a disease common 
to the patient population available to the research team.  As blockages become more 
severe and subsequently flow becomes more impaired, patients become symptomatic, 
predominantly experiencing pain while walking, called intermittent claudication.  
However, the vast majority of patients (>75%) which suffer from PAD were 
asymptomatic, according to a study involving nearly 20,000 Dutch adults 40-75 years of 
age [24]. It should be noted that if left undiagnosed and/or untreated, severely impaired 
blood flow can lead to pain while resting, ischemic ulcerations, and even gangrene, 
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resulting in amputation for nearly 1/3 of patients[25] and with a nearly 20% 1-year 
mortality rate[26]. 
 As mentioned earlier, segmental arterial studies and pulse-volume recordings are 
the most commonly used method of diagnosing PAD.  This diagnostic technique is 
performed in the following way: Blood pressure cuffs are attached at several locations 
along the leg, as shown in Figure 1.  The systolic blood pressure is measured at each cuff, 
just as it is done on the arm during a routine physical examination (pressure at which 
blood flow through the artery stops).  Next, the ratio of the blood pressure at each 
location along the leg to the brachial blood pressure is calculated.  The arterial systolic 
pressure measured at the ankle location is used to calculate the Ankle-Brachial Index 
(ABI), which is considered to be the golden standard for assessing arterial disease since 
1969[27].  An ABI below 0.90 is typically defined as an indicator of PAD[23], although 
0.95 is also used in some studies[24]. 
 Ultrasound Doppler techniques are considered adequate to assess the flow in the 
large (>7mm) arteries[28].  However, for the past 25 years[29], researchers have 
investigated microcirculation as it relates to PAD.  Several non-invasive optical 
techniques, to be expanded upon further in 
Chapter 3, have been used to study skin 
microcirculation[30] in clinical research 
settings.  These studies have predominantly 
utilized laser Doppler perfusion or 
transcutaneous oxygen measurement systems 
Figure 1: Blood pressure cuffs 
connected for Pulse Volume Recording 
and Segmental Pressure Study 
(www.viasonix.com) 
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which are commercially available, but are limited to <1mm penetration depth. One 
technique utilizing non-invasive measurements of skin microcirculation involves the full 
occlusion of the limb at >250mmHg for at least 3 minutes, followed by release.  This test 
allows comparison of absolute flow values during compression and following release as 
well as the temporal dynamic reperfusion process (specifically the time to peak inflow 
following release).  
 Although much of the above description of this section has focused on peripheral 
arterial disease, the exact nature of arterial disease can vary greatly, encompassing plaque 
build-up as well as endothelial dysfunction, which impairs the ability of the vessel to 
vasodilate.  The amount and quality of the arterial blood flow is one aspect of arterial 
disease, but vessel compliance (how the arteries can stretch and compress) is equally 
important. It is well known that diabetes (specifically type 2) is directly linked to loss of 
arterial compliance[31].   This assessment can be (and is routinely) subjectively assessed 
in a PVR/Segmental study. A semi-quantitative analysis is typically performed (for 
research purposes only) using high frequency (~7MHz) Doppler ultrasound[32] wherein 
the diameter of an artery (typically >2.5mm resting diameter) is measured before and 
after either compression and release or administration of a vasodilitory agent (such as 
nitroglycerin).  This ultrasound based method of measuring flow-mediated dilatation 
(FMD) requires precise (inter-observer error reported at over 1.3% [33]) technique and 
expertise to obtain consistent results for diagnosing arterial disease[34].   There exists a 
clinical need for a reliable, quantitative methodology to assess endothelial cell function, 
discussed further in Chapter 7. 
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 It is appropriate here to expand slightly on the effects of cigarette smoking as it 
relates to arterial disease and because cigarette smoking is the most important risk factor 
for development of PAD[35].  In fact, a recent (2014) report estimates that 20 million 
Americans have died because of smoking in the past 50 years[36]. Smoking, or even 
secondhand exposure, can lead to endothelial cell dysfunction, the core pathophysiology 
behind PAD[34, 37].  The exposure to carbon monoxide, present in cigarettes, reduces 
the oxygen carrying capacity of hemoglobin and enhances oxygen-hemoglobin affinity, 
making the release of oxygen more difficult[38].  It is suggested that this impairment 
directly leads to biologically adaptive responses, including an increased cell mass 
(absolute amount of red blood cells in vasculature)[39].  While the body is compensating 
for the impaired ability to deliver oxygen to tissue, other structural alterations of the 
blood vessels themselves are occurring due to habitual smoke inhalation[40], as detailed 
below. 
 It has been reported that brachial artery distensibility and compliance decreased in 
smokers, although the study found no other obvious hemodynamic changes associated 
with smoking[40].  While the changes in vessel compliance are reversible to some 
degree, the risk of peripheral arterial disease formation was similar to current smokers 
even 12 months after cessation[41]. More recent studies, using imaging ultrasound 
techniques to measure vessel diameter, have shown differences in reperfusion magnitude 
of smokers, where non-smokers had diameter increases of 10% during flow mediated 
dilatation versus 4% for smokers[33]. It has also been reported that smaller vessels have 
higher FMD responses[42], indicating that they would be a more sensitive indicator of 
disease.  However, the typical technique of ultrasound measured vessel diameter cannot 
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easily be performed on small (<2.55 mm) vessels [32].  Since the optical technology 
described herein measures capillaries and arterioles (<100um[43]), it seems likely that 
investigation of smaller vessels is imperative to understand the true vasculature effects of 
smoking. The research described herein expands on this concept of arterial compliance as 
a marker of disease and determines whether other changes to hemodynamics are observed 
in smokers.   
2.2 Normal Wound Healing 
 Before discussing the complexities of diabetic foot ulcers, and subsequently 
venous ulcers, it is prudent to discuss in brief detail the process of normal wound healing. 
Although the process is not completely understood, it is generally agreed upon that there 
are three separate, yet overlapping phases of wound healing, starting with 
hemostasis/inflammation, then the proliferative phase, and finally the remodeling 
phase[44]. As evident in Figure 2, the overlap between the phases ranges from a few (<7) 
days to several (>6) months[45, 46]. 
10 
 
Figure 2: The three phases of the wound healing process.  Reprinted from [Lamorte 
2002]. 
 Immediately following wound formation, hemostasis begins, followed by 
inflammation.  Hemostasis, which involves the cessation of bleeding by clot formation, is 
activated by contact between collagen and blood platelets[47].  The clot formation from 
hemostasis forms a provisional extracellular matrix for future cell migration[45].  The 
inflammation phase typically begins a few minutes after the injury occurs, and is 
characterized by erythema, edema, increased tissue temperature, and pain.  The 
vasodilation in this phase is a response to production of kinins and prostoglandins[48].  It 
is also in this phase that immune cells start to appear in the wound[49]. Following the 
arrival of the immune cells (specifically polymorphonuclear leucocytes), which are 
typically present for less than 3 days(assuming no bacterial contamination occurred[50]), 
macrophages (specifically alternatively activated macrophages) enter the wound (48-96 
hours post injury)[51]. 
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 In the early days of an injury (1-3 days), M1 macrophages are present, releasing 
inflammatory cytokines, recruiting other cells, and clearing the area of debris and bacteria 
[52]. Then, M2 macrophages take over and promote extra-cellular matrix (ECM) 
synthesis, angiogenesis, and matrix remodeling (4-8 days). The presence of both types of 
macrophages in the correct sequence is required for proper wound healing. If the M1-to-
M2 transition is disrupted, manifested as persistent numbers of M1 macrophages, the 
wound suffers from chronic inflammation and impaired healing [53-55], as will be seen 
below in the discussion of chronic ulcers. Following inflammation, the proliferative (or 
fibroplasia) phase begins and is characterized by the formation of granulation tissue in 
the wound[49].  In this phase, fibroblasts and endothelial cells become the predominant 
cellular components in charge of wound healing.  Fibroblasts are responsible for 
producing the majority of structural proteins used in tissue repair, specifically producing 
collagen to provide tensile strength to the scar[49].  It should be noted that the process of 
creating new tissue is energy intensive, thus requiring a greater supply of oxygen and 
nutrients than during homeostasis.  To meet this demand, angiogenesis occurs below the 
surface, providing new blood vessels to fuel the additional metabolic activity in the 
wound bed[49].  While this is occurring, the reepithelialization at the surface is typically 
complete within 48 hours for approximately incised wounds[49].  This entire wound 
healing process, as summarized above, is very different when infections or chronic 
disease is present.  Two specific instances relevant to this study are described below, 
specifically diabetic and venous ulcerations. 
2.3 Diabetic Ulcers 
 Diabetic ulcers, typically found on the feet of patients with type-II diabetes, are 
wounds which do not follow the normal wound healing cycle.  Diabetic ulcers are the 
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leading cause for lower extremity amputations in the industrialized world, resulting in 15-
46 times higher rates of lower extremity amputations compared to non-diabetics[56, 57]  
A more complete description of the financial and quality-of-life impact of diabetic ulcers 
is presented in Chapter 5. 
 The exact cause of diabetic ulcers is unknown, however the vascular disease and 
neuropathy of diabetic patients are the likely factors which turns minor trauma into non-
healing ulcers [58].  Peripheral arterial disease, as discussed earlier, is four times more 
prevalent in diabetics than in non-diabetics [59].  The impaired arterial supply to the foot 
can cause claudication, thickened nails, and thinned, shiny skin along the leg [60].  
Additionally, diabetes can lead to the reduction of capillaries and thickening of basement 
membrane of microvasculature, which ultimately impairs the exchange of oxygen 
between the blood and the tissue[61].  As the microvasculature gets further impaired, 
basic functions become impaired, including autonomic regulation[62], leading to reduced 
sweating and subsequent dry, cracked skin on the feet.  Combining these skin alterations 
with sensory neuropathy, diabetics can experience unperceived trauma (such as abrasion 
from footwear), ultimately resulting in a diabetic ulcer formation. 
2.4 Venous Ulcers 
 It is important to distinguish between diabetic and venous ulcers. Whereas 
diabetic ulcers are related to an arterial disease, venous ulcers are related to chronic 
venous insufficiency.  As mentioned earlier, chronic venous insufficiency involves 
incompetent valves in the venous return system, leading to accumulations of edema in the 
interstitial space along limbs [1].  The severity of chronic venous insufficiency is 
13 
qualitatively assessed using the CEAP scale, which ranges from 0 to 6 [63], and is shown 
below in Table 1. 
 
Table 1:CEAP Classification of Venous Disease Progression[63] 
 Patients presenting with reticular veins, edema, hyperpigmentation, or open ulcers are 
typically classified into the appropriate CEAP grade following, or in combination with, a 
venous reflux study which is performed to assess the progression of the disease in a more 
quantitative fashion.  The reflux study generally involves compression of the veins of the 
leg (femoral, popiteal, saphenous) using the Valsalva (manual) maneuver or a pneumatic 
compression sleeve.  The rapid and consistent pneumatic cuff deflation allows more 
reproducible quantitative assessment of venous reflux[64].  Immediately following the 
deflation of the cuff, duplex ultrasound (combination of B-mode and Doppler) using a 
linear 1D array between 7.5 and 13MHz [65] is taken to detect how long reflux, or 
backwards flow, lasts.  Reflux beyond half a second is considered pathological[66].  The 
determination of which valves are incompetent and how severe the reflux is can thus be 
used to determine the best effective course of treatment.  This may involve laser or 
radiofrequency ablation to prevent blood from flowing back into the greater saphenous 
vein[67].   
Grade Description
C 0 No evidence of venous disease.
C 1 Superficial spider veins (reticular veins) only 
C 2 Simple varicose veins only
C 3 Ankle edema of venous origin (not foot edema)
C 4 Skin pigmentation in the gaiter area (lipodermatosclerosis)
C 5 A healed venous ulcer
C 6 An open venous ulcer
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 Prior to reviewing the optical devices used in this study it might be beneficial to 
add that the exact reason why ambulatory venous hypertension and edema collection 
impair the wound healing process is not fully established. One theory involves fibrin 
cuffs, wherein the interstitial edema prevents oxygen from being directly diffused into the 
tissue[68].  Other recent theories suggests that the capillaries are actually plugged leading 
to the release of free radicals by white blood cells[69] or that fibrinogen and other 
macromolecules leak into the dermis and "trap" growth factors and other matrix proteins, 
making them unavailable for normal tissue repair [70].  
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Chapter 3: Review of optical non-invasive devices for vascular 
assessment 
The purpose of this chapter is to provide a brief summary of the currently available 
(either for research purposes or commercially) optical technologies to assess tissue 
properties and/or hemodynamics and their limitations at assessing ulcers and vascular 
disease.  The technologies described below are thermal imaging, diffuse reflectance 
spectroscopy, hyperspectral imaging, and finally laser Doppler perfusion.  Following the 
description of the principles and limitations of the previously developed optical 
technologies, the optical systems used in this research is described in Chapter 4. 
3.1 Introduction 
With the discovery of coherent laser light in the early 1960s, combined with the 
prior advances in computer processing speed and miniaturization of semi-conductor 
components, there has been rapid growth in the use of light for medical diagnostic 
purposes in the past half-decade.  Light, as a diagnostic technique, has advantages and 
disadvantages which vary between modalities, but can be generalized.  Diagnostic light is 
non-ionizing, has excellent soft-tissue contrast (when compared to x-rays)[71], fast data 
acquisition times (even capable of near-real time analysis), and is relatively inexpensive 
(in comparison to Magnetic Resonance Imaging or Computer Aided Tomography 
Scanning)[71].  The predominant disadvantage of optical imaging is that it has poor depth 
penetration, typically limited to several (<10) centimeters, even in the wavelength (λ) 
range from 400-1350nm, where absorption in tissue is weakest[71].  However, this 
limitation does not impact the ability of light to assess epidermal tissue properties, which 
is the focus of the work presented here. 
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3.2 Thermal Imaging 
 Thermal imaging is a technique to measure the emitted blackbody radiation of an 
object.  All objects warmer than absolute zero emit blackbody radiation, meaning that 
this imaging technique requires no source (the object is the source).  The emissive power 
of human skin (typically in the 2-14 µm wavelength range)[72], is strongly dependent 
upon temperature (T), as seen in the Stehan-Boltzmann law: Eb = σT4, where σ is the 
Stefan-Boltzmann constant [73].  The peak emissivity of human skin is at the 10 µm 
wavelength and modern thermal imaging systems are acutely sensitive to this 
wavelength[74].  
 Thermal imaging techniques date back to the 1970s, when two competing 
technologies began to emerge, the first being liquid-crystal contact thermography and the 
other a non-contact blackbody infrared imaging system[75].  Liquid-crystal 
thermography has since been rendered obsolete, primarily due to the combination of low 
thermal resolution (±0.5C), slow response time(>60 seconds), and the fact that the 
contact system could modify the temperature of the tissue being measured[75, 76].  Since 
the 1990s, there has been an increased availability of high resolution (512 x 512 pixels) 
fast scanning (>100 frames per second) cameras capable of thermal resolutions exceeding 
0.001° C[77]. 
 The basic setup of a modern thermal imaging system includes an array of 
detectors in the focal plane of a lens.  That lens, however, cannot be made with glass, 
because glass absorbs strongly at wavelengths near 10μm [78].  Therefore, the lenses 
used in thermal imaging systems are typically made from germanium [73].  The detectors 
must be calibrated using objects of known temperature if an absolute measurement of 
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temperature is needed.  This is important for longitudinal studies or even studies 
involving multiple images on the same day, as non-calibrated systems have poor 
accuracy (± 2°C)[75].   Because tissue has a high absorption coefficient (25-30 cm-1 at 
wavelengths between 2.2 and 5µm[78]), only radiation which is emitted from the surface 
of the skin can be assessed using thermal imaging techniques[73]. 
 Thermal imaging has been used to assess vascular abnormalities of the body 
ranging from tissue at risk for developing pressure ulcers [79] to the diagnosis of 
peripheral vascular occlusive disorder (deep vein thrombosis[80, 81] and coronary artery 
disease[82]).  Thermal imaging is best equipped to measure areas of inflammation, 
ischemia, or any other condition resulting in an abnormal supply of blood to the tissue 
(for thermal imaging purposes, blood=heat), therefore, the use of thermal imaging to 
assess peripheral arterial disease is based on the premise that the tissue will have an 
abnormal blood supply if the disease is present. As the abnormal tissue may be as little as 
1° C different from the healthy tissue[72], establishing a thermal equilibrium with the 
ambient temperature is imperative.  This is typically performed by having the patient 
acclimate to the room’s specifically selected temperature, requiring at least 15 minutes 
prior to measurements. 
 One study investigating peripheral vascular disease determined that locations with 
varicose veins were 0.7° to 1° C higher than the surrounding tissue[72].  This was 
ascribed to the fact that varicose veins are more superficial than healthy veins, leading to 
a supply of blood that is closer to the surface and able to emit more blackbody radiation 
than a normal vein[72].  Another patient of the same study, presenting with a deep vein 
thrombosis, showed an elevated temperature in the affected region, ascribed to the 
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inflammation and clotting associated with a thrombus[72].  It should be noted that this 
feasibility study assessed individual patients and matched findings with known medical 
disorders, leading to questionable blindness of the study.  This technique would also not 
be capable of staging the severity of the disease, which would be of interest in a 
screening technique.  
Researchers have looked into the use of thermal imaging to assess chronic ulcers 
for over 40 years  [79].  One such study investigated the temperature of ulcerated and 
non-ulcerated feet of the same patient, showing that the temperatures of ulcerated feet 
were, on average, 5.6° F higher than those of non-ulcerated feet(p<0.0001)[83].  In 
addition to diabetic ulcers, venous ulcer related skin temperature changes have been 
reported in several published studies [84, 85].  A daily monitoring of one patient with 
chronic venous insufficiency but no initial open ulcer discovered that in the days 
preceding subsequent ulceration, a sudden drop followed by an increase in temperature 
was observed, suggesting venous ulcers result from an ischemic event followed by a 
reperfusion injury [85].  It is of relevance to state that none of these studies had more than 
10 enrolled patients, precluding any statistical analysis, but they do show the potential 
infrared imaging has to assist in the diagnosis of ulcers or vascular diseases.  In 
summation, thermal imaging can distinguish vascular anomalies between healthy and 
diseased limbs, however the thermal regulation required for absolute measurements 
makes the system cumbersome for clinical use. 
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3.3 Diffuse Reflectance Spectroscopy 
 Diffuse Reflectance Spectroscopy (DRS) is an optical method, employed by the 
author’s research team in previous studies [86, 87], which uses visible and near infrared 
light (typically 400-1500nm wavelengths) to measure hemoglobin concentration and 
oxygenation of blood in superficial (<1mm depth) capillaries.  The DRS device typically 
consists of an optical fiber bundle with randomly dispersed source and detector fibers.  
The white light from the source lamp enters tissue and either gets reflected, absorbed, or 
scattered.  Any light which is either reflected from the skin surface (called specular 
reflection) or gets scattered within the skin and returns to the surface is transported by the 
detector fibers to a spectrometer.  The spectrometer disperses the light into a spectrum, 
which gets analyzed by either a photodetector array or CCD chip and converted to an 
electrical signal[88].  A simplified diagram of the overall system can be seen below in 
Figure 3. 
 
Figure 3: Schematic of a typical diffuse reflectance spectroscopy system.  The excitation 
light source is typically a bulb or arc-lamp emitting broadband visible and near infrared 
radiation.  Reprinted from [88]. 
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 The intensity of the returning light is inversely related to the number of absorbing 
molecules in the tissue.  Depending on the specific wavelength being investigated, this 
could be oxygenated hemoglobin, deoxygenated hemoglobin, water, or some other 
biological chromophore (see Figure 4 for absorption spectra). 
 
Figure 4: Absorption of hemoglobin and water (450-1000nm wavelengths), assuming 
14mM tissue hemoglobin concentration and 70% water.  Based on hemoglobin extinction 
coefficients from  [89] and water absorption coefficients from [90].  Image reprinted from 
[91] 
To highlight the wavelengths which are most absorbed (which chromophore is most 
present), it is common to convert the reflectance spectrum to an absorbance spectrum, 
where peaks indicate the wavelengths which are absorbed the greatest amount.  This 
technique requires the system to be calibrated with a pure white sample (100% 
reflectance at all wavelengths) and pure black sample (100% absorbance at all 
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wavelengths).  The absorbance spectrum is calculated by taking the inverse logarithm of 
the ratio of the measured intensity signal, I(𝜆𝜆), to the reference intensity signal Iref(𝜆𝜆)[92].   
  A(𝜆𝜆) = -log10[ I(𝜆𝜆) / Iref(𝜆𝜆) ] 
                   Equation 1: Absorbance Spectrum calculation 
The relative (note: not absolute) contribution of each chromophore can be determined by 
fitting the measured spectrum to a reference spectrum for each chromophore[92].  The 
relative nature of this technology limits the ability of the system to compare one subject 
to another.  It should be noted that the DRS system is capable of utilizing the 
wavelengths in the visible 500-650nm range because the penetration depth is less than 
1mm.  As discussed in the next chapter, the DNRS and DCS optical systems used in this 
study cannot use these wavelengths, as the high absorption (>2cm-1) results in no 
returned light at depths exceeding 1mm.  Accordingly, the wavelengths were modified to 
the 680-900nm range in the DNIRS and DCS systems to overcome this limitation. 
 Diffuse Reflectance Spectroscopy has been used previously to assess peripheral 
arterial occlusive disorder.  One study utilized blood pressure cuffs to initiate reactive 
hyperemia in patients’ legs[93].  Blood pressure cuffs were placed above the ankle and 
the cuff was inflated, held for 3 minutes, and then released.  Measurements were taken 
with the DRS at set intervals from 0-240 seconds.  The absorption was calculated using 
reference spectra of pure oxygenated and deoxygenated hemoglobin.  The study showed 
that healthy patients (n=25) achieved an immediate spike of hemoglobin following cuff 
release whereas patients complaining of claudication (n=125) had a delayed (12 seconds 
vs. 100 seconds) reperfusion.  Finally, patients diagnosed as having severe claudication 
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failed to elicit any reperfusion spike, rather showing a subtle, slow increase in blood 
inflow over the 4 minutes of recovery.  Although the relative changes throughout the 
measurement session yielded statistical significance (p<0.001) to differentiate those with 
PAD and those without, the values could not be compared across patients due to the 
relative nature of the technology.  In summation, the relative measurements and less than 
1mm penetration depth limit DRS’s ability to be clinically relevant, especially as 
superficial blood supply is highly sensitive to external temperatures (therefore 
temperature acclimation is often necessary). 
 
3.4 Hyperspectral Imaging 
Hyperspectral imaging (HSI) is a spectroscopy method which measures cutaneous 
oxygen in the skin and creates a 2-dimensional map of oxygenation values.  The actual 
principle behind is similar to the Diffuse Reflectance Spectroscopy system mentioned 
earlier. The primary difference is that while DRS obtains an absorbance spectrum from a 
single point source, HSI captures many spectra over a wide (for example, 400x460 pixels, 
1mm pixel resolution[94]) focal plane [95-98].  Similar to the DRS system, HSI devices 
begin with a broadband light source (ranging from visible to infrared wavelengths) which 
illuminates the tissue of interest.  A camera with a tunable optical filter (used to select 
specific wavelengths of interest) collects intensity levels at each wavelength, then stitches 
the images on top of each other (ensuring spatial alignment)(see Figure 5).  Like DRS, 
relative absorbance spectra of oxy- and deoxy-hemoglobin can be calculated when 
compared to a white reference and the values (typically oxygen saturation, SaO2) at each 
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pixel can be displayed on an anatomical map[95, 99].  Because this is a reflectance based 
modality, the penetration depth is limited to several hundred microns[100]. 
 
Figure 5: A diabetic foot ulcer imaged with color photography (left) and hyperspectral 
technology (left).  The color scale indicates oxy-hemoglobin values along the vertical 
axis and deoxy-hemoglobin values along the shorter horizontal (brightness)axis.  The 
radial grid pattern was added for research purposes to track locations of data points.  
Reprinted from [98]. 
 
 Hyperspectral imaging has a wide range of applications, from airborne remote 
sensing [101]to a food quality control tool [102].  Relevant to this work, HSI has been 
used for the assessment of chronic wounds since the early 2000s[99].  One study used 
HSI to observe hemoglobin concentrations at several time points along the healing 
process of a diabetic ulcer[99].  A later study from 2007[98] showed the ability of HSI to 
differentiate healing from non-healing ulcers based on the levels of oxy- and deoxy-
hemoglobin levels in the wounds (both were significantly greater in non-healing vs. 
healing).  This method could predict healing in diabetic ulcers with a 93% sensitivity and 
86% specificity[98]. 
 It was not until late 2011 when a study utilized HSI to observe differences in 
patients with and without PAD[103]. The study found that deoxyhemoglobin values were 
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statistically (p<0.005) higher on the plantar surface for limbs not suffering from PAD 
compared to those without PAD.  No other sites were found to be statistically different, 
nor were any oxygenated hemoglobin values (at any site along the calf nor the dorsal and 
plantar surfaces of the foot).  The inability to distinguish PAD in more locations or other 
wavelengths likely stems from the limited penetration depth(several hundred microns 
[100]) of the system. 
 
3.5 Laser Doppler Perfusion 
Laser Doppler Perfusion Monitoring (LDPM) is the optical modality which is most 
similar to the Diffuse Correlation Spectroscopy system utilized in this research.  The 
technology utilizes frequency shifts of scattered light, which directly relate to 
microvascular blood flow (perfusion)[104].  Optical fibers deliver near infrared light to 
the skin.  The photons get scattered by moving particles in the tissue (predominantly red 
blood cells) and undergo frequency shifts (Doppler Effect), which are proportional to the 
velocity of moving particles.  The scattered light which returns to the surface gets picked 
up by a second optical fiber (typically located 0.25mm away[104]) connected to a 
photodetector, which detects the spectrum of frequency shifts.  The collected data is 
analyzed using algorithms to convert the data to Laser Doppler Flux (LDF) values which 
are proportional to the average velocity and number of the red blood cells[105].  It should 
be noted that some systems, typically called Laser Doppler Perfusion Imaging (LDPI), 
use a scanning mirror in a non-contact manner to get LDF values at many different 
pixels, resulting in a 2D map of perfusion values. One commercially available LDPI 
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systems creates 256x256-pixel blood flow images in roughly 4 minutes (spatial resolution 
of ~1 mm) [105].   
 The first use of LDPM to measure microvasculature blood flow was in 1972[106].  
By 1994, studies of microcirculation in venous leg ulcers has been published using LDF 
techniques[107].  This study reported elevated levels of capillary flow (both volume and 
velocity) in ulcerated limbs compared to non-ulcerated limbs.  This study led to the 
concept of using skin perfusion techniques to monitor the healing process of venous 
ulcers.  However, a later study by Junger et al in 1996 showed no differences in LDF 
before and after healing in patients with venous ulcers, indicating LDPM alone is 
insufficient for monitoring the healing process of ulcers[108].  Other ulcer related studies 
[109-112] found that microcirculation of granulation tissue in ulcers (be they diabetic, 
venous, or pressure ulcers) was elevated compared to intact nearby skin. 
 In 2005, Morales et al described a technique of using laser Doppler perfusion 
monitoring to differentiate patients with peripheral arterial disease and those 
without[113].  The technique used post-occlusive reactive hyperaemia (PORH) to assess 
the magnitude and time for the foot to reperfuse following occlusion with a blood 
pressure cuff around the thigh.    It was discovered that those patients with PAD showed 
statistically significant delays (p<0.001) in reperfusion spikes (in the study called “time 
to resting perfusion”) and reduced ratios of maximum flow to resting flow (p<0.001).  
This validated the use of microcirculatory reperfusion monitoring to distinguish patients 
with and without PAD, however, as this technology produces relative values (and 
systems can vary from one to the other), flux values cannot be compared across patients 
or by other research teams. 
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 Overall, it can be seen that there is a need for an absolute optical technology 
capable of measuring tissue hemodynamics at depths approaching 1cm.  Such a 
technology would allow for distinguishing pathological arterial flow as well as 
quantification of wound healing.  Diffuse Correlation Spectroscopy when combined with 
Diffuse Near Infrared Spectroscopy meets all of these needs and therefore were the ideal 
systems to use for the research presented here. 
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Chapter 4: Diffuse Correlation Spectroscopy 
4.1 Background/Theory 
Diffuse Correlation Spectroscopy is an imaging method based upon the principals 
of photon correlation spectroscopy, which analyzes the temporal fluctuations of light 
which is transmitted through tissue.  Dynamic light scattering or photon correlation 
spectroscopy is a method that has been used since the 1970’s, originally designed to 
study the dynamics of molecular motions in solutions, biopolymers, and liquid crystals 
among others [114-116].  Since then, and more relevant to this research, this technology 
has been successfully implemented, and validated, in animal studies [117-120], in human 
brain studies [121, 122], in muscle [123], and in tumor monitoring (head and neck [124], 
breast [125, 126]). Validation of DCS in some cases has been provided by comparing the 
results of those obtained using power Doppler ultrasound [127], laser Doppler [128] and 
arterial spin labeled MRI [129].  DCS analyzes the temporal autocorrelation function of 
scattered light. The way light scatters depends upon the experimental setup and the 
material through which the photons propagate.  This section begins with the description 
of single scattering theory and then proceeds to the more physiologically relevant 
multiple-scattering mode.   
4.1.1 Single Scattering 
In a single scattering medium, photons are scattered only once (or not at all) 
before they exit the sample.  If the scatters within the medium are particle-like objects 
which move, the intensity of light received by a detector will vary over time.  The 
fluctuations in intensity carry information regarding the motion of the particles[130].  
The information can best be discerned using an autocorrelator.  The autocorrelation 
function is a mathematical way of representing fluctuations in the refractive index and 
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connecting the scattering intensity (I) of a particle at time t, with its scattering intensity at 
a later time (t+τ), when the particle will have also moved in the coordinate system.  Its 
mathematical representation in single scattering tissues is seen in Equation 2[131].  
𝐺𝑠(𝑟, 𝜏) = 〈𝐼(?̅?, 𝑡) ∗ 𝐼(?̅?, 𝑡 + 𝜏)〉〈𝐼2〉  
Equation 2:Autocorrelation function in single scattering medium 
Alternatively, assuming Brownian motion, Equation 2 can be rephrased as 
𝑮𝟐(𝝉) = 𝟏 + 𝒆−𝟐𝑫𝑩𝒒𝟐𝝉 
where q2 is the square of the scattering wave vector (comprised of the wave number and 
the angle between the source and detector) and Db is determined by the Einstein 
equation, which holds: 
𝐷𝐵 = 𝑘𝐵𝑇6𝜋𝜂𝑟 
Equation 3:Stokes-Einstein Equation for diffusion of a sphere through a liquid 
This single scattering equation can be used in-vitro (and was used for device calibration 
and initial testing, described in 4.3), however for tissue measurements, a multiple 
scattering model must be employed, due to the highly scattering property of biological 
tissue.   
4.1.2 Multiple Scattering 
As the name implies, in a multiple scattering environment, a photon is scattered off 
multiple particles before exiting the sample.  In this setup, the source and detector are 
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typically located on the same side of the sample (as opposed to opposite sides or 90 
degrees for single scattering).  In the case of multiple scattering, there is an accumulated 
phase shift (registered as a delay) by each scattering event.  To perform the necessary 
calculations, several assumptions must be made.  The first assumption is that each 
individual photon path is uncorrelated.  This is a logical assumption as the path of one 
photon should not affect the path of another photon. It has also been confirmed by several 
publications[132-134].The second assumption is that the medium is homogeneous. This 
assumption only applies to soft tissue, and would not work for measurements through the 
skull and tissue (the boundary between the bone and soft tissue violates the assumption of 
a homogenous medium).  Finally, there is an assumption that each scattering event is 
independent, a valid assumption given the fairly homogenous nature of the tissue being 
probed.  Each scattering event causes a small phase shift (calculated below) in the light.  
In a highly scattering medium, the average scattering value, represented by <cosθ>, 
approaches (g), the anisotropy factor of the medium[135], typically 0.9 in human tissue, 
meaning each scattering event averages a 26° phase shift.  This anisotropy factor relates 
to the reduced photon scattering length (typically defined as l*s) and the photon scattering 
length (1/µs) by the equation l*s=1/(µs(1-g))[136].  The anisotropy factor (g) should not 
be confused with the autocorrelation functions (G1 or G2).   
In biomedical applications, the dynamics of capillary blood flow can be described 
as a Brownian motion of red blood cells[135], where the mean squared displacement of 
these randomly moving particles is given by Equation 4, where 𝑫𝑩 is the diffusion 
coefficient of the red blood cells and τ is a time interval, defined as the time during which 
the displacement of red blood cells is equal to their mean displacement.  
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〈⧍𝒓𝟐(𝝉)〉 ≥ 𝟔𝑫𝑩𝝉 
Equation 4: Brownian motion of red blood cells 
The reason that red blood cell movement is best modeled by a Brownian motion model 
rather than a ballistics or random ballistics flow fit is unclear[135].  It should be noted 
that the tissue is made up of non-moving tissue as well as moving particles.  Therefore, a 
parameter α is introduced to represent the ratio of moving to non-moving particles in the 
tissue.  The effective tissue blood flow can be characterized by using the red blood cell 
diffusion coefficient 𝑫𝑩combined with a parameter α, which is proportional to the 
volume of red blood cells in the tissue, resulting in the term 𝜞 = 𝜶𝑫𝑩. This term 𝜞, when 
being used to assess the movement of blood in-vivo, is called the Blood Flow Index, or 
BFI. In several publications [125, 137-139], the diffusion equation for a continuous (un-
modulated) wave source was solved (semi-infinite geometry) and the expression for the 
intensity autocorrelation function 𝒈𝟏 was obtained as an exponential function, depending 
on a constant 𝒌𝑫.A complete description of the governing equations was given by 
Li[140].  Of those, the most relevant solutions are shown in Equation 5, where 0k is the 
photon wave number (2π/λ) in the tissue.  
𝑮𝟏(𝝆, 𝝉) = 𝟑µ𝒔′𝟒𝝅 �𝒆−𝒌𝑫𝒓𝟏𝒓𝟏 − 𝒆−𝒌𝑫𝒓𝟐𝒓𝟐 � 
where 
𝑘𝐷 = �3𝜇𝑎𝜇𝑠′2 + 6𝜇𝑠′ 2𝑘02𝛤𝜏 
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𝑟1 = �𝜌2 + (𝑧 − 𝑧0)2         𝑟2 = �𝜌2 + (𝑧 + 𝑧0 + 2𝑧𝑏)2 
Equation 5:Autocorrelation function in multiple scattering medium 
The absorption and reduced scattering coefficients, aµ (cm-1) and 'sµ  (cm-1) 
respectively, can be determined from frequency domain measurements taken by the 
DNIRS system described elsewhere [13, 18, 141-144].  The absorption coefficient is a 
measure of the number of photons absorbed in a medium per unit length.  The reduced 
scattering coefficient is actually comprised of the scattering coefficient (number of 
photons scattered per unit length in a medium) and the anisotropy factor (g) discussed 
earlier.  Whereas this method does not provide the blood velocity in (m/s), as does a 
Doppler ultrasound or Doppler OCT, it still provides a physical measurement, the 
diffusion coefficient (cm2/s).  For example, photon correlation spectroscopy measures the 
diffusion coefficient of moving red blood cells and thus a representative dynamic 
measure of blood flow can be obtained. However, this technology alone can currently 
provide only relative changes of blood flow because an absolute value for the diffusion 
coefficient requires knowledge of absorption and scattering coefficients of the tissue.  
The device proposed here can provide this diffusion coefficient because it will be coupled 
with the already functional DNIRS device (described below in chapter 5) which provides 
the optical properties of the same tissue being probed (the µa and µs’ values discussed in 
Equation 5).  Variations in optical properties (due to approximations of the absorption 
and scattering coefficient by other systems, which estimate the values) can lead to 
variations in perfusion calculation of up to 40%[145].   Therefore, real-time 
quantification of optical properties by the DNIRS system improves the accuracy of 
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perfusion calculations, specifically when compared to commercial laser Doppler 
perfusion systems (described in chapter 3). 
 
4.2 System Design 
 In this section, the DCS system used in this study is described. The diffuse 
correlation spectroscopy system is comprised of 3 essential components.  The first is a 
long-coherence (~10m) 780nm laser diode (CrystaLaser, Reno NV).  This system emits 
light which remains in phase for great distances.  This feature is important as 
monochromatic light (L=∞) is a fundamental assumption of the DCS system.  
Additionally, the coherence length must be longer than the photon path length 
distribution between a point source and point detector (to ensure the light returns to the 
detector as coherent, as required in the analytical solution), calculated as 
𝑃 = �𝑣𝜌24𝜋𝐷 𝑒�𝑣𝜇𝑎𝜌2𝐷 𝑠−3 2� 𝑒−𝑣𝜌24𝐷𝑠𝑒−𝜇𝑎𝑠 
Equation 6: Photon Path Length Distribution 
where v is the speed of light in the medium, ρ is the source-detector separation, s is the 
total photon path length, and D is the diameter of the source.   
Using this equation, it can be seen that in a medium with a µs’=10cm-1 and µa=.1cm-1 
and with a source detector separation of 1cm, the path length distribution is 0.3m.  
Therefore, a system with a 10m coherence length is sufficient.  The optical fiber that 
delivers the light to the tissue is a multimode optical fiber.  Conversely, the optical fiber 
which detects the light and connects to the detector (the next component to be described) 
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is a single mode fiber.  This 6µm diameter fiber is used as it can detect intensity 
fluctuations in a single speckle area.  It also helps limit the amount of light returning to 
the detector, as it can saturate at levels greater than 2 million photons per second. 
 The detector for the DCS system is a single photon counting module (SPCM) 
(Pacer, Palm Beach Gardens, FL). This 4 channel component is capable of registering 2 
million photon counts per second per channel.  There is a 50 nanoseconds dead time 
between pulses, but the system can detect the arrival of a single photon with an accuracy 
of ~350ps.  Each time a photon is detected, a 30ns wide transistor-transistor logic (TTL) 
pulse (minimum of 2.5 volts) is outputted via a BNC connection. 
 The output of the SPCM is connected to a multi-tau autocorrelator 
(Correlator.com, Shen Zhen, China).  The autocorrelator is arguably the center of the 
DCS system.  As such, the operation of this component should be briefly discussed.  The 
autocorrelator is separated into multiple registers (typically 16 bins per register, although 
this system’s first register has 32 bins).  The width of the bin doubles for each register, 
with the smallest bins being 160ns in width.  The device registers the number of photons 
arriving per bin.  Once that timeframe is complete, the number is passed to the next bin 
and the first bin gets refilled with a new number of photons.  Once the register is full, the 
values are placed into the larger bin of the next register.  The autocorrelation functions 
are calculated before each shift.  In the unnormalized intensity autocorrelation function, 
the number of photons arrived in the ith bin is multiplied by the photons from the 0th 
(first) bin, seen in equation 
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Figure 6: Block diagram of DCS system. 
𝐺2(𝜏𝑖) = 〈𝑛𝑖 ∙ 𝑛0〉 
Equation 7: Unnormalized Intensity Autocorrelation Function 
 
This average is continuously performed throughout the entire acquisition time.  It can be 
seen that the smaller bins are averaged more often than the larger bins (two averages for a 
320ns bin for each average of a 640ns bin).  The overall autocorrelation curve, G2(τ), is 
constantly updated and normalized before being passed to the computer.  With the 
number of registers used by the system, the bin sizes range from 160 nanometers up to 
several minutes (if needed).  Given the speed of typically moving red blood cells in the 
tissue being examined (typically less than 1mm/s[146]), bins greater than 1 millisecond 
are unnecessary (as the autocorrelation function will be 0). 
 With the principle components described, the overall device schematic can be 
seen below in Figure 6.  The autocorrelator directly connects (via USB) to the computer 
controlling the 
system.  It can 
be seen in 
Figure 7 that the 
source and 
detector fibers 
for the DCS are 
combined with 
the fibers from 
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the Diffuse Near Infrared Spectroscopy system (described in chapter 5).  This insures that 
the two systems are probing the same sample (nearly) simultaneously.  A Teflon housing 
holds all 10 fibers, as its inert, non-wetting properties help for cleaning and safety. 
 
Figure 7: Combined DNIRS/DCS Optical Probe Layout 
 The system is controlled using a LabView (National Instruments, Austin, TX) 
based interface, which controls both the DNIRS and DCS systems via two USB 
connections.  As described further in Chapter 7, the system first takes a single DCS scan 
(which can be averaged over any desired timeframe, typically 1.5-3 seconds, see Figure 
35) then completes a DNIRS scan (which typically takes 2.5 seconds to complete all 
wavelengths through all source fibers).  It is optimal to minimize the time between paired 
DNIRS and DCS measurements as the properties of the tissue being evaluated are 
constantly changing.  Therefore, a longer delay between the two will result in errors, due 
to the fact that the optical properties calculated by the DNIRS are used to calculate the 
BFI from the DCS. 
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4.3 Calibration and Testing 
 The Diffuse Correlation Spectroscopy system was validated and calibrated using 
previously developed techniques.  It is worth mentioning that the DCS system has been 
validated in previously reported publications[120, 123, 125, 129] and is not the focus of 
this research.  Calibration was conducted to ensure that the newly constructed device was 
operating properly and produced reproducible, reliable results.  The testing methods were 
conducted in both the single scattering and multiple scattering regimes.  The simplicity of 
the single scattering setup lent itself to be the initial testing method, after which the 
optical probe seen in Figure 7 was constructed to use in multiple scattering mode. 
 The setup for 
single scattering testing 
consisted of a clear 
cuvette with a source and 
detector fiber 90 degrees 
to each other. The emitted 
light scattered off a single 
scatterer and entered the 
detector fiber.  For the 
purposes of calibration/testing, polystyrene spheres of known diameters were used.  
Using equations 1 and 2, it was possible to calculate the size of the spheres using the 
diffusion coefficient measured by the system.  For comparison, a commercial particle 
sizer (Malvern, Westborough, MA) which operates off the same principle of dynamic 
light scattering, was also used to calculate particle size.   
Figure 8:G(1) Autocorrelation functions for polystyrene 
beads of different diameters 
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 The particle sizes used were 202nm, 350nm, and 500nm.  Larger particle sizes 
quickly settled or resulted in multiple scattering, limiting us to these three particle sizes 
(which were available in the laboratory).  The raw autocorrelation curves are shown in 
Figure 8, wherein it can be seen that the smaller particles were moving faster and resulted 
in a correspondingly faster decaying autocorrelation curve (shift to the left).  The 
concentration used was 7.5ppm of the beads in water.  The DCS calculations for size 
averaged a 20% error from the actual particle sizes compared to an 11% error from the 
Malvern system.  Since the measurements of interest for medical research involve a 
multiple scattering regime, this test was primarily used to ensure the components were 
working properly and the expected trend with autocorrelation functions was present.  
With these expectations, the test was deemed a success and resulted in the progression to 
a multiple scattering regime. 
Figure 9: autocorrelation functions for different source detector separations 
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 The first test using multiple scattering mode involved placing the source and 
detector fibers at 3 separate distances and 
measuring a homogeneous solution of Intralipid (a 
fat emulsion used in optical testing as it has the 
absorptive properties of water and the scattering 
properties of human tissue [147]).  In this setup, it 
was expected that all distances would yield the 
same diffusion coefficient, but that the increased distance meant the light would undergo 
more scattering which manifested as a shift to the left in the autocorrelation function.  
The results of this test are shown in Figure 9, where it can be seen that the expected trend 
was observed and the average diffusion coefficient was 8.1E-9 cm2/s with a 3% standard 
deviation for all 3 distances. 
The next 
test involved 
assessing the 
linearity of the flow 
measurements by 
the DCS system.  
As most clinical 
trials involved 
relative changes 
before or after some 
manipulation was conducted, the device’s linearity was paramount.  To test this, a flow 
Figure 11: Setup of flow phantom measurement 
Figure 10: Cross sectional model of 
flow phantom 
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phantom was created using silicone and small (<3mm inner diameter) clear rubber tubing 
(see Figure 10).  The tubing was placed in a spiral pattern 2-3mm below the surface of 
the phantom before it set.  After the silicone set, the resulting flow phantom allowed 
Intralipid to flow through the capillary spiral at known rates using an electric syringe 
pump.  The complete setup is shown Figure 11. 
The flow of the 0.4% Intralipid solution through the tubing was varied from 
Figure 12: Autocorrelation curves of flow phantom 
at different flow rates 
Figure 13: Diffusion coefficients of flow 
phantom at different flow rates 
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0.5mL/min to 4mL/min.  The plot of the raw autocorrelation curves can be seen below in 
Figure 12.  In this figure, it can be seen that whereas the no-flow calculation fit (dashed 
line) was in line with the raw data (solid line), the 4 flow curves had relatively poor fits, 
specifically with the initial time point (the β value).  This is likely due to the relatively 
large (3mm) diameter of the tubing, which is over two orders of magnitude greater than a 
capillary (<15µm).Nevertheless, when converted to an actual diffusion coefficient (DB), 
the values were plotted against the actual flow rate to determine the linearity of the 
system (Figure 13) which was determined to be 1.00 using a simple linear fit model. 
 Although the flow phantom allowed the linearity of the system to be documented, 
it does not represent human epidermal hemodynamics.  For this reason, the next set of 
calibration testing was performed directly on humans.  For testing purposes, the easiest 
manipulation of blood flow involves the inflation of a blood pressure cuff and its eventual 
Figure 14:Blood Flow Index (squares)  and 
[HbO2], [TotHb], and Oxygen Saturation (lines) 
measured with DCS/DNIRS prototype on the 
forearm of a healthy volunteer while a blood 
pressure cuff was inflated (left dashed line) and 
deflated (right dashed line), where the initial 
blood flow was normalized to 1. 
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release, eliciting a reactive hyperemic state, where additional blood flows to the area to 
expedite a return to homeostasis. 
It is worth reiterating that physiologically, BFI reflects microvascular blood flow 
and has units of [cm2/sec], a unit which differs from the blood perfusion units 
[ml/min/100 g] traditionally used in ultrasound Doppler experiments and arterial spin 
labeling MRI [148, 149]. However, values of BFI from DCS systems show statistically 
significant correlation with blood flow results from Doppler ultrasound and MRI systems 
[129, 150]. To test the ability of the DCS device to quantify blood flow in vivo, the 
forearms of healthy volunteers were monitored while blood flow to the arm was occluded 
using an inflatable cuff. Optical measurements were taken continuously starting 1 minute 
before the cuff was inflated, for 2 minutes while the cuff was inflated to 180 mmHg, and 
then 2 minutes after the cuff was deflated. The measured relative blood flow index (rBFI 
= BFI / BFIO, where BFIO is the initial BFI) from DCS and relative oxygen saturation 
(rOxySat = OxySat / OxySatO) and relative oxy-hemoglobin concentration (r [OxyHb] = 
[OxyHb] / [OxyHb]O) from DNIRS are presented in Figure 14. These results demonstrate 
that: (1) The time scale of rBFI changes is faster than that of rOxySat (~10-15 seconds 
vs. ~1-2 minutes), and (2) DCS measurements of blood flow are more sensitive to 
hemodynamic changes than DNIRS measurements of hemoglobin oxygenation (a 60-
70% decrease of rBFI vs. ~35% decrease of rOxySat from baseline was measured while 
blood flow was occluded, and a 50-100% increase of rBFI vs. ~20% increase of rOxySat 
from baseline was measured when the cuff was released).  
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Chapter 5: Monitoring Human Diabetic Foot Ulcers with Diffuse NIR 
Spectroscopy 
 As mentioned earlier, the fact that not every treatment heals every ulcer puts a 
great emphasis on proper monitoring of healing to determine when a change in treatment 
is necessary.  As wound sizing is a subjective and error-prone method (not to mention its 
inability to assess the underlying tissue), the clinical need for an optical, quantitative, 
assessment of wound healing was apparent. A small (n=16) pilot study[151] and 
subsequent larger (n=46) study [152]were conducted to determine the feasibility of using 
Diffuse Near Infrared Spectroscopy as a predictor of healing in diabetic foot ulcers.  This 
chapter describes the larger 46 patient human study which included a cost analysis of 
potential savings if using the 4 week prediction to determine when to change ineffective 
therapies.    
5.1 Introduction 
The epidemiology and financial impacts of diabetic ulcers were previously discussed in 
Chapter 1.  Briefly, DFUs account for nearly 75,000 cases per year[5] and result in $5 
billion per year in direct costs[6].  The excessive costs (ranging from $50 to $1,800 per 
week) can be minimized it the appropriate therapy is quickly realized and applied. 
  As not all treatments are effective for all patients, the ability to distinguish 
efficacious treatments from ineffective ones would be beneficial for wound healing 
clinics to reduce the cost and duration of healing a diabetic ulcer.   The standard 
procedure for evaluating wound healing involves manually obtaining length, width, and 
depth information and comparing weekly changes.  The Wound Healing Society has 
reported that a 40% reduction in wound surface area over a 4 week period indicates a 
current treatment is working and should be continued, while those treatments which fail 
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to produce 40% closure should be altered or halted[12].  This guidance is further 
supported by a study which found wound size alone to be a 58% positive predictor (and 
91% negative predictor) of ultimate healing, based on a 53% reduction in wound size 
over 4 weeks[15].   
 The wound size reduction is a strong predictor of wound healing, however it has 
several pitfalls.  These include inter-clinician variability in wound size measurements[14]  
and incorrect size estimates based on length-by-width measurements for large or irregular 
shaped wounds [153].  Beyond measurement error, wound size only conveys superficial 
aspects of the wound and does not account for the health of the wound environment and 
underlying tissue which means that infections can go unnoticed.  Wounds which appear 
to be getting smaller may have underlying infection including osteomyelitis or poor blood 
supply and may reopen.  The focus of this study was to predict wound healing based on 
objective data relating to the health of the tissue in the wound bed.   
5.2 Materials and Methods  5.2.1 Diffuse Near Infrared Spectroscopy Hardware 
Frequency 
domain Diffuse near 
infrared spectroscopy 
(DNIRS) utilizing diffuse 
photon density wave 
methodology uses light in 
the optical window of 
Figure 15:Left: Schematic of DNIRS device probe where dark 
dark cylinders represent source fibers and light cylinders are 
detector fibers.  Right:  An overhead view of the probe.  Dark 
gray circles show source fiber positions (S1-S6), light gray 
circles show detector 
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650 to 850nm, where the optical absorption in tissue is minimal  allowing information to 
be obtained about the optical properties of tissue  for  depths up to several 
centimeters[154].   The original DNIRS method and used device has been described 
previously[17, 18, 155].  Briefly, the updated prototype has several (six) source fibers 
which deliver 70 MHz intensity-modulated light from laser-diodes at 685nm or 830nm 
wavelengths. The light passes through a MEMs optical switch, which allows the 
transmission of one wavelength of light at a time through one source fiber.  The light is 
then sent through the subsequent source fibers before the wavelength is changed and the 
process repeats for all source fibers and wavelengths. Finally, the backscattered light is 
collected by two detector fibers located in the experimental probe between 4-16mm (as 
shown below inFigure 15) from the various source fibers and is registered by avalanche 
photodiodes.  The device then uses a quadrature demodulator to measure shifts in phase 
and changing amplitude in the scattered light compared to incident light, both as a 
function of source-detector separations.  These data points can then be fit into the 
diffusion approximation model and the optical absorption (µa) and reduced optical 
scattering (µs') coefficients can be calculated using MATLAB software (MathWorks Inc., 
Natick, MA).  The instrument was calibrated, and checked at each weekly measurement 
session, using  a silicone phantom of known optical properties to ensure stability of the 
device, as described in earlier publications[91, 156].  There was less than a 3% variance 
in week to week silicone phantom measurements, demonstrating the device's stability.  
 The primary chromophores found in tissue within the near-infrared window of 
685nm and 830nm are water, oxyhemoglobin, and deoxyhemoglobin[157].  As the 
extinction coefficients for these chromophores are known, by measuring both the 
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reduction in signal amplitude and change in phase of the individual wavelengths, it is 
possible to determine the absorption (µa) and scattering (µs') coefficients of the tissue.  
From there, the concentrations of oxy- and deoxy-hemoglobin in the wound bed can be 
calculated.  Oxy-hemoglobin (HbO2) and deoxy-hemoglobin (Hb) were calculated using 
the following equation: 
𝜀𝐻𝑏
𝜆 [𝐻𝑏] + 𝜀𝐻𝑏𝑂2𝜆 [𝐻𝑏𝑂2] + 𝜇𝑎,𝐻2𝑂𝜆 [%𝐻2𝑂] = 𝜇𝑎,𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙𝜆  
Equation 8: Calculation of hemoglobin and water concentrations based on optical 
absorption 
   
where 𝜀𝐻𝑏𝜆 [𝐻𝑏] and 𝜀𝐻𝑏𝑂2𝜆 [𝐻𝑏𝑂2] are the molar extinction coefficients of deoxy- and 
oxy-hemoglobin[158], 𝜇𝑎,𝐻2𝑂𝜆  is the optical absorption coefficient of pure water[159], and [%𝐻2𝑂] is the percentage of water in the measured tissue, which is assumed to be 70%.  
Total hemoglobin (Hb total) was calculated by the simple addition of Hb and HbO2.   
5.2.2 Human Study 
 Forty six patients with diabetic foot ulcers were recruited from Drexel University 
Wound Healing Center and Temple University Foot and Ankle Institute, both in 
Philadelphia, PA over three years.  The study protocol was reviewed and approved by 
both the Drexel University College of Medicine as well as the Temple University 
Institutional Review Boards.  All enrolled subjects were between the ages of 18 and 65.  
All patients had a documented history of diabetes mellitus of at least six months.  
Wounds were limited to the ankle or foot, were secondary to complications from 
diabetes, and presented with a minimum surface area of 1cm2.  Before enrollment, 
patients underwent arterial assessment and treatment if necessary.  Patients were only 
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enrolled in the study if the ankle-brachial index was >0.75, as lower indices would 
necessitate vascular intervention to restore adequate blood supply.  All wounds were 
debrided of any necrotic tissue before the patient entered the study and any diagnoses of 
active osteomyelitis resulted in an excision of the infected bone and treatment with 
appropriate antibiotics before enrollment of the patient.  All enrolled patients had 
standard wound care treatment as determined by the physician, including weekly or bi-
weekly debridement, offloading, and moist wound dressings.  If indicated, active wound 
healing treatments were utilized including but not limited to negative pressure therapy, 
hyperbaric oxygen therapy, and active skin substitutes.  Optical measurements were 
performed weekly during the patients regularly scheduled appointments or as often as 
patients were available.  Healing wounds were 
measured until the wound closed, with a maximum of 
20 visits.  Wounds were declared non-healing if they 
required surgical revision, resulted in definitive 
amputation, or remained open at the 20th visit. 
5.2.3 DNIRS measurements 
The DNIRS optical measurements were taken each 
visit at multiple locations, which had to be adjusted 
slightly as the wound changed shape and size over 
time. Measurements were taken (1) directly on the 
wound, (2) on the intact periwound area, and (3) at an 
ipsilateral, healthy location that is at least 2cm from 
the wound to act as a baseline so each patient was 
Figure 16: Example of locations 
for different DNIRS 
measurement locations.  If the 
wound is located elsewhere, the 
control location is at least 2cm 
away from the edge of the 
wound.  At the wound and 
control locations, two 
measurements were taken with a 
90 degree rotation of the probe 
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their own control.  An example of these measurements is shown below in Figure 16.  The 
wounds size and geometry dictated which locations and measurements were possible (for 
example, the wound was too narrow and deep to get DNIRS measurements with current 
probe design).   
 
Determination of wound size 
Immediately following DNIRS measurements, a digital photograph was taken of the 
wound with a paper ruler in the frame.  This ruler allows the determination of the scale of 
the picture to accurately determine wound size.  The wound boundaries were traced by 
hand and the surface area was calculated using a program[160] created using MATLAB 
software (MathWorks Inc., Natick, MA). 
 
5.3 Results 
Of the total 46 patients enrolled in the study, 17 healed completely and 29 were 
determined to be non-healing.  The calculated oxygenated and total hemoglobin 
concentrations were found to be initially elevated in all wounds when compared to the 
control location.  Subsequently, in healing wounds, the [Hb02] and [Hb total] trended 
downward and converged with the control location measurements.  Given the device's 
accuracy, this same pattern was not seen in non-healing wounds, which showed relatively 
large fluctuations from week to week, and never converged with the baseline values.  No 
trend for deoxygenated hemoglobin concentration in neither healing nor non-healing 
wounds was found.  All comparisons between healed and non-healed were made using a 
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two-tailed unpaired student T-test, the typical test used to differentiate two independent 
groups.  Initial total hemoglobin concentrations in the healing and non-healing group 
were compared and were found to be statistically significantly different (p<.001).  
However, the predictive power of this measurement had sensitivity and specificity both at 
72%, i.e.  no better than the currently used ruler method.   
 Typical healing and non-healing plots are shown below in Figure 17 and Figure 
18, with corresponding images of the two ulcers in Figure 19.  The slope of the linear 
regression line fit to the data points is used as the predictive factor for differentiating 
healing and non-healing wounds.  Previous data suggests that both wound and periwound 
(edge) measurements show the same trends in optical data[18] and thus one can be 
substituted for the other if a particular measurement location is impossible to measure 
(due to wound location or geometry).  After the DNIRS data was collected, a linear 
regression curve was fitted to the data points and the slope was calculated from this line.   
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Figure 17: Typical Healing Wound DNIRS Plot.  (Top Left) Wound sizes measured 
during each clinical visit.  (Top Right) Plot of total hemoglobin concentration over time. 
(Bottom Left) Plot of oxygenated hemoglobin over time. (Bottom Right) Plot of 
deoxygenated hemoglobin concentration over time.  For all concentration plots, black 
circles( ● ) represent measurements on the wound, triangles (Δ) are periwound 
measurements, and the X's indicate control locations on the ipsilateral heel (at least 2cm 
from the wound). Reprinted from 
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Figure 18: Typical Non-Healing Wound DNIRS Plot.  (Top Left) Wound sizes measured 
during each clinical visit.  (Top Right) Plot of total hemoglobin concentration over time. 
(Bottom Left) Plot of oxygenated hemoglobin over time. (Bottom Right) Plot of 
deoxygenated hemoglobin concentration over time.  For all concentration plots, black 
circles( ● ) represent measurements on the wound, triangles (Δ) are periwound 
measurements, and the X's indicate control locations on the ipsilateral heel (at least 2cm 
from the wound). Reprinted from 
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Figure 19: Images of a typical healing ulcer (left) and a non-healing ulcer (right). 
Reprinted from 
 
 With the data collected, it was necessary to determine the cutoff slope between 
healing and non-healing wounds based on the collected data.  To determine this optimal 
cutoff value to distinguish healing from non-healing ulcers, Receiver Operating 
Characteristic (ROC) curves (shown below in Figure 20) were created.  These curves 
were used to optimize a threshold by evaluating the sensitivity (ratio of true positives to 
Figure 20: Receiver Operating Characteristic Curves of DNIRS Data (left) and Wound 
Size Data (right).  These plots display true positive rate (sensitivity) on the y-axis versus 
the false positive rate(1-sensitivity) on the x-axis. Reprinted from 
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Figure 21: Histogram of total hemoglobin concentration slopes of healing and non-
healing wounds measured over the total experimental timeframe.  The vertical dashed 
line indicates the -4µM/wk threshold. Reprinted from 
true positives plus false negatives) and specificity (ratio of true negatives to true 
negatives plus false positives) of a data set at a series of different possible thresholds until 
the value which best balances both specificity and sensitivity was established.  These 
curves determined that -4µM/wk for the change in total hemoglobin concentration was 
the optimal cutoff value for this data set.  This means that using -4µM/wk best 
distinguished healing from non-healing ulcers (see Figure 21).   
An additional ROC curve was created for the wound size data which determined that 
39% was the best cutoff for reduction in wound size to distinguish healing from non-
healing ulcers.  This value corresponds well with the 40% reduction in wound size 
recommendation of the Wound Healing Society.  With this -4µM/wk cutoff established, 
healing and non-healing wounds were predicted based on if the linear regression curve's 
slope was greater or less than this value.   
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Wounds showing a week to week trend more positive than this cutoff would be classified 
as non-healing while more negative trends (those quickly returning to baseline) would be 
classified as healing.  Overall it was seen that using this calculated -4µM/wk cutoff, the 
sensitivity and specificity of the predicted outcomes were high, resulting in an overall 
sensitivity of 0.88 and specificity of 0.93 when looking at the complete measurement 
record over the course of the wound.   
To determine a faster (closer to 4 weeks) and more sensitive (compared to the 
0.72 sensitivity of the ruler method) predictor of wound healing, a separate analysis was 
done on the first 4 weeks, to see the predictive power of the system in this short 
timeframe.  Although the four week timeframe was preferred, of the total 46 wounds 
enrolled in the study, only 15 patients returned at least 3 times within the first 4 weeks.  
To improve the statistics, any patient who had three measurements in the first five weeks 
was also included in this analysis, resulting in 24 patients.  As four weeks was preferred, 
all patients with sufficient data in those four weeks were analyzed up that point, and those 
with sufficient data at five weeks were analyzed over that time period, resulting in fifteen 
at four weeks and nine at five weeks.  Of these specific patients, the optical method’s 
sensitivity was 0.9 with a specificity of 0.86.  The average slope for healing patients was 
negative 11.5(standard deviation of 11.8) while the average slope for non-healing was 
positive 5.6 (standard deviation of 12.2), resulting in a statistically significant p<0.002.   
 Although these values show that the described method can differentiate healing 
and non-healing wounds in four weeks with statistical significance, they are best 
appreciated when compared to the current golden standard of wound size reduction.  
Using the guidelines established by the Wound Healing Society (which matches the 
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optimal cutoff value determined in the ROC curve found in figure 6) of 40% reduction in 
size over 4 weeks to determine efficacy of a treatment to result in healing, all the patient 
available patient data was analyzed using hand tracings and computer calculated surface 
areas.  This wound size analysis resulted in sensitivity of .76 and specificity of .72(AUC 
0.762) and had a statistically insignificant p<0.07.  These values correspond well with the 
predictive power of wound size previously reported in [15].  The predicted results of the 
complete study can be seen in Table 2. 
 
Table 2: Predictions of Healing and Actual Outcomes in Human Study. Reprinted from 
 
There were 4 instances where wound size incorrectly predicted non-healing but the 
DNIRS system (either in 4 weeks or total slope if 4 week was not available) did it 
correctly.  Conversely, there was instance where a healing wound was incorrectly 
predicted as non-healing using DNIRS, yet the change in size did correctly predict 
healing. Of the 8 instances of non-healing ulcers where size incorrectly predicted healing, 
the DNIRS system was correct in 7 of the instances (only two of which had 4 week 
predictions, both of which were correct).  There was only one instance where the DNIRS 
(both at 4 week and complete study) incorrectly predicted healing but the ruler method 
correctly predicted non-healing.  The 62% positive predictive value for wound size in this 
study matches well with the 58% positive predictive value reported by Sheehan et al[15], 
Healing Non-Healing Healing Non-Healing Healing Non-Healing
Predicted 
Healing 15 2 9 2 13 8
Predicted Non-
Healing 2 27 1 12 4 21
Optical Data Size Data
Full study timeframe First 4-5 weeks only First 4 weeks only
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who used the ruler method to predict healing in diabetic ulcers, and is 20 percentage 
points lower than the 82% positive predictive value (from this study) in the same 4 week 
period using DNIRS. The negative predictive value was 92% (essentially equal to the 
91% reported using wound size[15]). 
5.4 Cost Analysis 
 Given the DNIRS system's ability to differentiate healing from non-healing ulcers 
within a relatively short timeframe (4-5 weeks), the system could directly be used to 
reduce treatment costs and healing times by differentiating treatments which are causing 
the wound to heal versus those which are ineffective.  Currently, physicians must wait 
four weeks and determine the efficacy of the treatment based solely on wound size, 
which is difficult to quantify and is not strongly predictive.  However, using the DNIRS 
method, after 4 weeks of treatment and weekly scans, the calculated trend line could 
differentiate efficacious treatment modalities from non-efficacious ones, presumably with 
the same accuracy (91%).  This would result in no treatment lasting longer than 4 weeks 
if it does not ultimately heal the wound.  Using this concept, it was possible to 
retroactively assess all the treatments the patients received during the course of the study 
and postulate the potential savings were this system to be implemented.  All treatment 
sessions which extended beyond the initial 4 weeks but did not result in ultimate healing 
of the ulcer would be potential savings using this system.   
 Treatment modality data was only available for 30 of the total enrolled patients 
and those patients received up to seven separate treatments during the course of the ulcer, 
with the average patient undergoing three different wound care treatment methods.  Each 
treatment the patient underwent was marked out on a separate row of the wound's 
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timeline shown below in Figure 22.  
 
Figure 22: Treatment timeline of non-healing (top) and healing (bottom) ulcers. 
Reprinted from 
Treatments beyond the initial 4 weeks which did not result in ultimate closure of the ulcer 
were determined to be potential savings, and are demarcated as such with an "X" in all 
cases.  Since the physician was kept blinded to the DNIRS data during the treatment of 
the ulcers, best medical judgment was used to determine when to switch therapies.  
Typical timelines of both a healing and non-healing ulcer are shown below, where each 
block represented one week.  
 In Figure 22, it can be seen that Subject 2 (the top of Figure 22) received 35 
weekly treatments of a standard hydrogel dressing before being changed to Medihoney®.  
Of those 35 treatments, the use of this optical system could have indicated the treatment 
was ineffective after week 4(shown as the first 4 squares without "X's") so 31weeks (the 
squares with "X's") of that treatment could have potentially been avoided.  Likewise, 
Medihoney® was used for 2 additional weeks beyond the 4 week cutoff.  Ultimately, 
after five weeks of using the wound V.A.C.©, the patient underwent an amputation.  On 
top of the potential savings of nearly 35 weeks in avoidable treatment costs, this system 
could possibly have prevented the amputation which followed.  
  Meanwhile, it can be seen that Subject 33 (bottom of Figure 22) was using a 
combination of Hydrogel and Oasis® for 12 weeks, eight of which could have been 
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potential savings, before switching to PolyMem® Foam.  As this treatment did result in 
ultimate wound closure (in addition to all other standard protocol, including offloading, 
compression, debridement, etc), the optical data would show the wound is healing and the 
treatment could be continued until wound closure occurred, with no potential savings.  
For this reason, there are no "X's" during the PolyMem® Foam treatment in the figure.  
 The average potential saving per patient was determined to be $12,612.80, with 
maximum single patient saving of $56,800, which includes the direct costs associated 
with a potentially avoidable amputation.  In 3 of the 6 cases involving amputation, the 
DNIRS system correctly predicted non-healing whereas the ruler method incorrectly 
predicted healing.  Therefore, the conclusions reached would have been different and 
may have led to more timely recognition of the ineffectiveness of the treatments, which 
in turn could have avoided delays and further complications, including potential limb 
loss. Cumulative potential savings for these 30 patients exceeded $370,000.  This was a 
phase 1 study supported by research grants and it should be stated that the direct cost 
associated with this technology has yet to be determined; a fact that would likely impact 
the potential costs savings calculation. 
 
5.5 Discussion 
One of the biggest obstacles to chronic wound healing is that not every treatment works 
for every individual.  It can often take two or more treatment modalities to find one that 
helps achieve wound closure.  Minimizing time spent on ineffective treatments is 
therefore of the utmost importance in a clinical setting.   Prediction of wound healing 
based on manually measuring wounds is error prone, subjective, and has a relatively low 
58 
sensitivity.  The use of optical diagnostic systems like the Diffuse Near Infrared 
Spectroscopy device improves on standard practices by looking at the health of 
underlying tissue in the wound bed and not solely on the superficial appearance/size of 
the wound.  It was shown that the -4µM/wk change in total hemoglobin successfully 
distinguished healing from non-healing ulcers and there is even the possibility to 
correlate slopes between 0 and -4µM/wk with slower healing rates compared to those 
with slopes less than -4µM/wk. The measurements can be performed relatively quickly 
(<30 seconds) and be instantly plotted against previous data to show the presence of a 
trend towards healing or not. Furthermore, there are currently no products on the market 
which are capable of quantifying absolute concentrations of hemoglobin at the 3-5mm 
depth range of wounds utilizing the diffusion approximation.  Various methods have been 
used to examine the properties of the underlying tissue, including diffuse reflectance 
spectroscopy and hyperspectral imaging, but the penetration depth of these 
methodologies is limited to less than 1mm, respectively[95, 99, 161, 162].  Based on the 
results obtained, it would appear that this technology could potentially change not only 
the practice of wound healing, but more importantly, patients’ clinical outcomes. 
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Chapter 6: Venous Ulcer Treatment with Novel Ultrasound 
Transducer 
  
In this chapter, the optical systems described in previous chapters were used as diagnostic 
tools to assess the efficacy of an exploratory therapeutic approach to treating venous 
ulcers.  The therapy utilized was low frequency (20 kHz), low intensity (<100 mW/cm2, 
spatial peak temporal peak) ultrasound.  In a small pilot study, seventeen subjects were 
treated with either 20kHz ultrasound or a sham treatment for 15 minutes per session for a 
maximum of twelve treatments.  The selection of these parameters is based upon the 
results of a 20 subject pilot study investigating three different ultrasound exposures 
(20kHz for 15 minutes, 20kHz for 45 minutes, and 100kHz for 15 minutes)[163], wherein 
it was determined that 20kHz ultrasound in a 15 minute treatment resulted in statistically 
improved healing rates (p<0.03) compared to the control group.  In the study described 
here, healing was monitored by relative changes in wound area and by changes in 
capillary blood flow each week. It was hypothesized that non healing wounds had more 
underdeveloped capillary beds (resulting in a higher flow), whereas healing wounds 
would develop larger, mature vascular networks which have a lower total flow, 
comparable to non-ulcerated tissue. Additionally, two in-vitro studies were conducted 
using fibroblasts exposed to 20kHz ultrasound to confirm the ultrasound's effects on 
proliferation and cellular metabolism.  Patients receiving 20kHz ultrasound for 15 
minutes showed statistically faster (p<0.03) rate of wound closure.  The in-vitro results 
indicated that 20kHz ultrasound at 100mW/cm2 caused an average of 32% increased 
metabolism (p<0.05) and 40% increased cell proliferation (p<0.01) in fibroblasts after 24 
hours when compared to the control, non-treated cells.  Although statistically limited, this 
60 
work supports the notion that low-intensity, low-frequency ultrasound is beneficial for 
treating venous ulcers.   
6.1 Introduction 
Below, the encouraging results of a pilot human study (17subjects) indicating that 
low frequency (20 kHz), low intensity (<100 mW/cm2, spatial peak temporal peak) 
ultrasound can be used as an effective tool in chronic wound management, specifically 
treatment of venous stasis ulcers, are described. Although statistically limited due to the 
small (n=17) subject population, this study is of importance as no satisfactory in vivo or 
animal model, which incorporates all the complexities of chronic wounds, exists[164].  
 As described in Chapter 1, venous ulcers are a costly burden (>$25 billion [165]) 
on the healthcare system and impact over half a million Americans each year[166].   
Multiple factors contribute to the delayed healing of venous ulcers including ambulatory 
venous hypertension often associated with venous reflux, poor nutrition, advancing age, 
smoking, and medical compliance (i.e. following physician’s guidelines and 
recommendations)[167].  The direct wound care cost associated with venous ulcers 
exceeds $2,400 per month, but also is associated with  indirect costs due to limited 
productivity and quality of life issues related to  pain and depression [168].New therapies 
are needed to both directly help patients and to decrease the costs related to these 
wounds.  
  In terms of using ultrasound to treat venous ulcers, the common 
knowledge appears to be that reported in the review[169], where it was concluded that 
“the quality of studies supporting the effectiveness of ultrasound as a therapeutic 
modality in wound healing is rather poor” and hence “the scientific basis for the use of 
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ultrasound in wound healing is not well established”.  The outcome of the research 
presented herein not only expands the knowledge base related to interaction of ultrasound 
and biological tissue but also supports the notion that the use of low-intensity, low-
frequency ultrasound is beneficial for the treatment of chronic venous ulcers. 
 The primary decisions for ultrasound parameters involved choice of frequency 
range and intensity level used in insonification. To the best of the authors knowledge, Dr. 
M Dyson and her associates should be credited for their pioneering efforts of promoting 
in-vivo therapeutic ultrasound treatment of venous ulcers [170], performed at 1W/cm2 
and a frequency of 3MHz, with treatment times ranging from 5-10 minutes, depending on 
the size.  In a later publication[171], Young and Dyson suggested that 1MHz ultrasound 
at an intensity (SATA) of 100 mW/cm2 could be useful in accelerating the inflammatory 
and early proliferative stages of repair in full-thickness acute wounds in a rat model. The 
intensity level not exceeding 100mW/cm2 (spatial peak temporal peak) was selected 
intentionally, partly because it follows Dyson’ and her team’s findings, and also because 
it is considered safe even at prolonged (>250 minutes) exposure time, according to the 
2008 Statement on Mammalian In-vivo Ultrasonic Biological Effects from the American 
Institute of Ultrasound in Medicine[172].In the same Young study[171], it was reported 
that the application of somewhat lower frequency (750kHz vs. 1 MHz) resulted in faster 
healing, when compared the treatment outcome obtained at the higher frequency (3 
MHz). They ascribed this effect to non-thermal ultrasound mechanisms, such as stable 
cavitation and cavitation-related acoustic microstreaming, which are more likely to be 
present at the lower frequency. From the perspective of this work, it should be reiterated 
that the outcomes of [171]were observed in an acute wound model, as opposed to the 
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chronic wound environment found in venous ulcers and considered here.  In another 
relevant study [173], 24 chronic venous ulcer patients were exposed to 30kHz continuous 
wave ultrasound at 100mW/cm2 intensity for 10 minutes, three times a week. This 
treatment resulted in enhanced rate of wound healing (55.4% reduction in the treatment 
group vs. 16.5% reduction in the control group).In an in-vitro study[174] of 1 MHz (25% 
duty cycle at intensities ranging from 0.1 to 1 W/cm2) and 45 kHz (continuous wave at 
intensities 5-50 mW/cm2) ultrasound on fibroblasts, osteoblasts, and monocytes, it was 
determined that the 45 kHz treatment resulted in increased (compared with 1MHz 
treatment) production of collagen and non-collagenous proteins.  Based on the above 
described works and additional comprehensive literature search, including a review of the 
results of Sundaram, Mellein and Mitragotri[175], the ultrasound field exposure 
parameters presented in this study (100 mW/cm2 ISPTP with a pulse repetition frequency 
(PRF) of 1 Hz and duty cycle of 50%) were eventually chosen. 
 In the recently conducted clinical study of 20 subjects, patients were assigned to 
one of 3 treatment groups (20kHz for 15 minutes, 20kHz for 45 minutes, or 100kHz for 
15 minutes) along with one control group.  The study revealed that the 20kHz for 15 
minute treatment resulted in statistically improved (p<0.03) rate of wound closure 
compared to the control group.  For this reason, this treatment regimen was selected for 
the second pilot study described herein.  
Patients suffering from venous ulcers were exposed to ultrasound with the goal of 
determining the efficacy of the ultrasound.  This efficacy was determined by tracking 
reduction in wound size on a weekly basis as well as changes in vasculature as 
determined with Diffuse Correlation Spectroscopy (DCS).  Following the in-vivo study, 
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two additional in-vitro experiments were performed using the ultrasound parameters from 
the best performing group to confirm and examine the anticipated cellular effects of the 
ultrasound treatment. 
More specifically, the auxiliary in-vitro studies were designed to provide insight 
into the elements of ultrasound exposure which produce the largest cellular response as it 
relates to wound healing.  The working hypothesis for this study was that the 
insonification caused ultrasound cell proliferation (mitosis) and concurrently increased 
cellular metabolic activity.  Fibroblast cells were chosen as they have been previously 
shown by [174] to respond to low frequency (45kHz), low-intensity (30mW/cm2) 
ultrasound. Both intensity and pulse repetition frequency (shown to be biologically 
relevant by [176])were anticipated to play a role in ultrasound assisted wound healing, so 
they were included as two additional, adjustable variables in order to determine their 
effects on cellular metabolism (effects of the varying of PRF and intensities were not 
studied in the cellular proliferation experiment).   
6.2 Materials and Methods 6.2.1 Therapeutic tool: ultrasound applicator 
The construction and operation of the flexural transducer used in this study was described 
in detail in [177].  Briefly, the applicator, shown in Figure 23, was driven by a tone-burst 
with 1 Hz PRF (Pulse repetition frequency) and 500ms pulse duration, from a custom 
rechargeable battery-operated driving unit. The light weight (<100 g ) small foot print 
(approximately 35 mm x 35 mm x 10 mm) applicator was designed to be suitable for 
tether-free, fully portable wound healing applications.  The acoustic output of the 
applicator was determined in 22°C de-ionized water, using a calibrated hollow cylinder 
hydrophone, with a diameter of 2mm[178]. The pressure amplitude map of the 
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applicator’s acoustic output distribution is shown inFigure 24.  The pressure 
measurements were performed at a distance of 2.5 mm away from the transmitting 
surface of the transducer (to mimic a clinical application), and the applicator pressure 
amplitude was set to 55kPa (100mW/cm2 ISPTP ) prior to treatment. It has previously been 
determined that the transducer did not experience any self-heating and resulted in less 
than a 1° C increase in skin temperature with a 45 minute application. 
 
Figure 23: Photograph of flexural ultrasound applicator used in both in-vivo human study 
as well as in-vitro fibroblast study. Within the transducer, the 4 piezoelectric elements 
can be seen.  The specific spacing of the elements created a uniform field output, as 
depicted in Figure 24. 
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Figure 24: 2-Dimensional beam plot showing ultrasound field distribution of the flexural 
ultrasound applicator at the axial distance of 2.5mm.  It can be seen that the individual 
elements in the applicator work synergistically to create a uniform field distribution 
 
6.2.2 Wound size determination: digital camera 
 At the end of each treatment session, a digital photograph was taken using a 
Fujifilm Finepixs700 digital camera (Fujifilm Holdings Corp, Tokyo, Japan).  Each 
picture had a one inch marker in the frame, which allowed for the determination of the 
scale of the picture for precise determination of wound size.  The wound boundaries were 
traced by hand and the surface area was calculated using a previously described program 
[160] created using MATLAB software (MathWorks Inc., Natick, MA). 
 
6.2.3 Optically assessed wound healing 
 As described previously, our research team has a long history of using optical 
techniques to assess wound healing[13, 17, 18, 86, 142, 144, 155]. Briefly, near infrared 
(NIR) technologies are established methods of measuring changes in vessel density in a 
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non-invasive manner, well suited for human research. The optical setup used for this 
study consisted of two inter-dependent and complementary optical systems. The DNIRS 
system provides data related to the static condition of the tissue whilst the DCS allows 
the hemodynamic flow in the capillaries to be determined and quantified.  The DCS and 
DNIRS systems used here are nearly identical to those described in Chapters 4 and 5, 
therefore only a brief description of the differences will be described. 
 The original DNIRS device described in Chapter 5 utilized two wavelengths, 
685nm and 830nm, to quantify concentrations of deoxygenated and oxygenated 
hemoglobin, respectively.  This system was designed and optimized for the assessment of 
healing in DFUs.  However, differences in pathophysiology with CVUs required 
adjustments to the DNIRS system, specifically hyperpigmentation and edema. 
Chronic venous insufficiency often results in changes in skin pigmentation in the 
gaiter region of the leg, but the exact nature and pathogenesis of these changes are poorly 
understood[179]. Although it is traditionally thought that staining is due to extravasated 
red blood cells which lyse and decompose to form haemosiderin deposits[180, 181], more 
recent work has shown that this process only contributes to darkening of skin surrounding 
tissue with lipodermatosclerosis and ulceration[179]. Although hyperpigmentation causes 
no discomfort nor poses risks to patients, it did make using near infrared devices to assess 
tissue changes challenging, as the DNIRS device operates entirely on the principle of 
light being absorbed only by hemoglobin within the blood vessels. Hence, the 
superfluous presence of iron was factored into the methodology for measuring venous 
ulcers. The second tissue pathophysiology involves the edema present in patients with 
venous insufficiency. Edema is a heterogeneous fluid made of proteins and erythrocytes 
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Figure 25: Optical Absorption in Diagnostic Window 
(courtesy of International Cancer Therapy Center) 
(and water), which have leaked out of blood vessels and remain pooled in the lower limbs 
due to malfunctioning valves in the veins[182]. This results in an un-quantified amount of 
fluid, which contains iron (specifically in the form of pooled venous blood, with 
deoxygenated hemoglobin) and 
water (which also absorbs NIR 
light, as seen in Figure 25). 
Healthy tissue has an average 
water content of 70%, a statistic 
used in the calculation of oxy- 
and deoxy-hemoglobin 
concentrations by any DNIRS 
device operating off the 
principal of Diffuse Photon Density Wave Propagation (see Equation 8 from 5.2.2 
Human Study). To understand the role of edema on the calculations of hemoglobin 
concentrations, the water quantity (as a percent) was directly measured, instead of being 
assumed. Therefore, the first change in the team’s DNIRS approach was to directly 
measure the amount of water in the tissue.  This was performed with a 3rd laser source, 
operating at 920nm, selected due to the fact that it’s absorption by water is over 1 order 
of magnitude higher than that by hemoglobin[183], yet was not too high as to violate the 
principle for diffuse photon density wave propagation that µa<<µs’.  By measuring the 
absorption and scattering of this wavelength, a numerical assessment of water amount 
was ascertained.  With the amount of water correctly measured, the accuracy of the oxy 
and deoxy-hemoglobin measurements with the other two wavelengths was improved.  
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The importance of this was that the optical properties of the tissue needed to be fed into 
the other optical system. As noted above, the DNIRS collected data were related to the 
static condition of the tissue and therefore, an additional technique (Diffuse Correlation 
Spectroscopy, or DCS) was utilized which provided dynamic information, specifically 
the flow of blood in the capillaries and microvasculature (at a depth of approximately 
5mm) and quantified as Blood Flow Index (BFI).  The exact theory and design of the 
DCS system is described in full detail in Chapter 4: Diffuse Correlation Spectroscopy. 
It was hypothesized that the blood flow in the wounded tissue would be higher 
than the flow in the healthy, in-tact skin, due to inflammation and excess of immature 
capillary beds.  Over time, healing wounds should show a decreased flow (relative to the 
baseline) as the inflammation is reduced and the capillary beds are replaced by more 
mature vasculature.  Optical measurements were taken directly on the wound before and 
after treatment.  An additional measurement was taken on the plantar surface of the foot 
to act as a control.  Measurement sessions lasted less than 2 minutes. 
6.2.4 Patient selection 
 Seventeen patients with chronic venous stasis ulcers were recruited from Drexel 
University Wound Healing Center.  The study protocol was reviewed and approved by 
the Drexel University College of Medicine Institutional Review Board (IRB).  Eligible 
patients were between the ages of 18 and 65, had a documented venous ulcer for at least 8 
weeks with a surface area at least 1cm2(as determined by standard length times width 
ruler measurement[184] by the nursing staff) and had a CEAP (a classification system 
comprised of clinical severity, etiology, anatomy, and pathophysiology) clinical severity 
of 6.  Subjects with moderate to severe vascular insufficiency (ankle brachial index <.75 
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or toe-brachial index <.5) were excluded, as it impairs tissue oxygen perfusion and 
subsequent wound healing[185]. 
All enrolled subjects continued to have standard wound care treatment as 
determined by the physician, including weekly or bi-weekly debridement, compression 
therapy, edema control, and any prescribed topical therapies.  Upon enrollment, subjects 
were randomly assigned to one of two experimental groups: 15 minutes of 20 kHz 
ultrasound or 15 minutes of sham (no treatment).  The active ultrasound treatment was at 
100mW/cm2 SPTP. 
6.2.5 Patient treatment 
 During each treatment session, topical anesthetic (typically Lidocaine) was 
applied to the wounds before ultrasound insonification.  The ultrasound applicator, 
wrapped in an acoustically transparent sterile wound dressing (Tegaderm®, 3M, St. Paul, 
MN)and coated with sterile ultrasound gel (Aquasonic 100, Parker Laboratories, Inc., 
Fairfield, NJ), was placed directly on the wound and affixed using surgical tape (see 
Figure 26).  The applicator was then turned on for 15 minutes.  Following insonification, 
the applicator was removed and a photograph for wound size determination was taken. 
As mentioned before, optical measurements were taken before and after treatment. There 
were no adverse events reported throughout the pilot study. 
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Figure 26: In-vivo experimental setup showing ultrasound applicator covered with an 
acoustically transparent wound dressing with ultrasound gel coupled to the wound bed.  
The entire setup is attached to the wound with surgical tape. 
 
6.2.6 Fibroblast preparation and Ultrasound exposure 
 Mouse fibroblasts (3T3-swiss albino cells) were purchased from ATCC 
(American Type Culture Collection) and were all used between passage numbers 7 and 
15 (a method of tracking how many times a cell populations has been re-cultured).  The 
fibroblasts, chosen due their documented role in wound healing[186], were seeded in 
sterile 6-well transparent plates at 1 X 104and 2 X 104cells/well (two concentrations were 
used to rule out any possible effects on the assays used; p>0.4) in 2 mL’s of Dulbecco's 
modified Eagle’s medium (Life Technologies, Carlsbad, CA) with 10% bovine sera.  The 
6-well plates were then sealed off to maintain the sterile environment. The cells were 
cultured between 18 and 20 hours to allow cells to adhere to the wells and begin cell 
growth cycle, throughout which cells were maintained in an incubator at 37° C, with 5% 
CO2 and 80-90% humidity.  After this initial growth period, cells were removed from 
incubation for exposure with the ultrasound, which occurred at room temperature.   
 For the cellular metabolism in-vitro experiment, all cells were exposed to 20kHz 
ultrasound for 15 minutes (chosen based on treatment parameters of the in-vivo study).  
To investigate whether the ultrasound parameters could be manipulated to produce the 
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greatest cellular response relative to the control group, two additional pulse repetition 
frequencies (10 and 20 Hz) and intensities (50 and 200 mW/cm2 ISPTP) were studied in 
addition to those from the human study.  The complete exposure matrix for the cellular 
metabolism study is shown in Table I.  The exposure parameters of Table I marked in 
gray match those used in the human study.  Each exposure parameter was repeated 6 
times. 
 A final in-vitro experiment was conducted to investigate cellular proliferation as it 
relates to ultrasound treated cells.  The treated cells for this experiment were exposed to 
20kHz ultrasound, 1Hz PRF, and 100mW/cm2ISPTPspatial-peak, temporal-peak intensity 
for 15 minutes (a combination of exposures found to produce the greatest response 
relative to the control groups from the prior two studies, shown in the results section). 
 Prior to the complete description of the in-vitro experimental setup, it is important 
to note that the potential of introducing undesirable artifacts during the insonification was 
recognized and given thoughtful consideration.  Specifically, the geometry of the 
exposure container (see Figure 27) was intentionally chosen to closely mimic the in-vivo 
exposure conditions.  Similarly, the biological assays chosen were carefully selected to, 
respectively, determine cellular metabolism (alamarBlue) and proliferation (BrdU). 
 When the cells from both experiments were ready for insonification, the 
ultrasound applicator (Figure 23) was placed below the 6-well plate to transfer the 
ultrasound energy in a non-contact, sterile manner, shown in Figure 27.  The geometry of 
the experimental setup was chosen to mimic (as closely as possible) the in-vivo clinical 
exposure conditions.  The acoustic output of the applicators was adjusted to account for 
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any attenuation experienced due to the relatively thin (1.3 mm, or 0.017λ) plastic bottom 
of the well plate.   Treatment and control (sham) exposures were performed 
simultaneously in separate well plates, to minimize any potential variability between 
samples, while eliminating concerns of sham group exposure to any potential reflected 
ultrasound. Due to the relatively long (75mm) wavelengths of 20kHz ultrasound, the 
pressure gradient across the sample (~2mm) at any time point was negligible.  With this, 
the experimental setup was not subject to nodes or anti-node formation within the 
medium and therefore was not a concern. Even in the worst case scenario, cells would be 
exposed to a maximum of 200 mW/cm2 ISPTP, which, under the experimental conditions 
used here, complies with FDA safety guidelines.  After exposure, cells were cultured for 
an additional 24 hours prior to the cellular metabolism and proliferation assays.   
 
Figure 27: In-vitro experimental setup showing ultrasound applicator and sterile plate 
containing fibroblasts in a growth media.  Ultrasound applicators produced 20kHz 
ultrasound with a corresponding wavelength of ~75mm.  Potential influence of the 
experimental setup regarding reflections and standing waves is further described in 
Section E. 6.2.7 Cellular metabolism assay 
 After a 24-hour incubation period following insonification, the cell medium was 
replaced with fresh solution of 90% media with a 10% alamarBlue (Invitrogen Corp., 
Carlsbad, CA), a reagent used for assessing cellular metabolism in-vitro[187]. This 
reagent assesses cellular metabolism by showing an increase in the level of fluorescence 
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as nutrients in the media are consumed.  This level was then measured using a 
fluorescence reader (Tecan US Inc., Morrisville, NC) with an excitation wavelength of 
560nm and an emission wavelength of 590nm.  The fluorescence of the treatment cells 
was compared to the control cell plates to determine percent increase.   There were 6 
wells for each of the treatment and control groups. 
6.2.8 Cellular proliferation assay 
 After the same 24-hour incubation period following insonification, cell 
proliferation was measured using a 5-bromo-2’-deoxyuridine (BrdU)assay, a standard test 
for measuring cellular proliferation[188].  The BrdU calorimetric assay procedure was 
performed as per the manufacturer’s protocol (Roche Scientific, Indianapolis, IN).  The 
cell media was removed and BrdU, diluted 1:1000 in media with 10% sera, was added to 
the cells for 3 additional hours of incubation prior to adding the fixing and denaturing 
agents from the kit. The newly synthesized cellular DNA that incorporated the BrdU was 
then labeled using a BrdU labeling agent which attached to the BrdU.  The reaction 
product was then quantified by measuring the absorbance in a fluorescence reader (Tecan 
US Inc, Morrisville, NC) at 370 nm (referenced at 492 nm). The absorbance of the 
treatment cells was then compared to the control cell samples to determine relative 
changes(%) in proliferation.   There were 6 samples for each of the treatment and control 
groups. 
6.3 Results 6.3.1 Clinical, in-vivo study 
  
Of the total 17 patients who enrolled in the study, 16 patients received at least 3 
treatments.  Their data was used for analysis.  Of the 16, nine were enrolled in the 
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treatment group and seven were in the control group.  One of the seven control wounds 
healed, and four of the nine treated wounds healed.  Over the course of the treatment, the 
treatment group averaged a 45% reduction in wound size area, compared to a 50% 
increase in wound size for the control group.   
Since patients 
received different 
numbers of treatments 
over different 
timeframes, due to 
missed appointments or 
rapid healing, the rate of 
wound healing (% 
decrease per week) was 
also calculated.  The average rate of wound closure for the treated patients was 
8.2%/week whereas the control group had an average increase in wound size of 
7.6%/week (see Figure 28), a statistically significant difference (p<0.04).  It was 
calculated that the effect size of the therapy, using the Cohen's d value (an effect size 
indicator for differences between two means, where the d represents the standard 
deviations between the two means), was 0.95 (effect sizes are considered large when 
d>0.8). This effect size means that the difference between the treated and control group 
was 0.95 standard deviations.  Representative photos of a non-healing and healing patient 
from the sham and a patient receiving 20kHz, 15 minute ultrasound are shown in Figure 
30. 
Figure 28: Rate of change in normalized wound size for 
control (left) and treatment (right) groups. p<0.05 
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Figure 29: Week to week change in blood flow index for healing (n=5) and non-
healing (n=11) venous ulcers using Diffuse Correlation Spectroscopy System 
(error bars represent standard error) p<0.01 
 
Figure 30: (color online) Representative wound photos from a non-healing ulcer in the 
sham group (left) and a healing ulcer in the 20kHz, 15 minute treatment group (right).  
Images feature line tracing the wound perimeter as part of the wound sizing software 
 
As mentioned earlier, the change in capillary flow over time was also measured to 
assess healing.  To validate the initial hypothesis that healing wounds would show a 
decrease in flow over time, the rate of change in capillary flow for healing and non-
healing patients was plotted (see Figure 31).  It can be seen that the healing group had a 
significant (p<0.01) decrease in flow over time whereas the non-healing patients showed 
a slight increase in flow over time, confirming the hypothesis presented.  This assessment 
was then applied to the treated and un-treated patients, where it was shown that 
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ultrasound treated patients showed a significant (p<0.01) reduction in blood flow 
compared to the control group.  These results are shown in Figure 30.  Treated wounds 
had an average change in blood flow of  −1𝐸−9 𝑐𝑚2 𝑠�
𝑤𝑒𝑒𝑘
  whereas the sham group averaged 
an increase of 7.3𝐸−10 𝑐𝑚2 𝑠�
𝑤𝑒𝑒𝑘
. 
6.3.2In-vitro results 
The results of the cellular metabolism assay comparing the various treatment groups to 
the control are shown below in Figure 32.  A two-factor ANOVA analysis (used to 
determine variance between multiple equally sized groups with two independent 
variables, which were intensity and pulse repetition for this study) determined that, 
whereas there was no statistical difference between the applied pulse repetition 
frequencies (p>0.05), the intensity was statistically significant (p=0.021).  A post-hoc 
Tukey test (a typically used method to evaluate which means are statistically different 
from one another in a multiple group analysis) confirmed that the 100mW/cm2ISPTPgroup 
Figure 31:Change in capillary blood flow over time as an Effect of ultrasound 
therapy on promoting healing.  Blood flow was measured by DCS device 
(n=15).  Error bars represent standard error. p<0.01 
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statistically outperformed both the 50 mW/cm2ISPTPgroup (p<0.05) and the 200mW/cm2 
ISPTP group (p<0.04).   
 
Figure 32: Average increase in metabolic activity of fibroblast cells for cells exposed to 
ultrasound with respect to cells that were not exposed to ultrasound (incubator 
control/sham).  The groups are separated into the three intensity levels (50,100, and 200 
mW/cm2 ISPTP), and within each level, the dark gray bar represents the 1 Hz PRF, the 
medium gray represents 10 Hz PRF, and the light gray represents 20 Hz PRF.  Bars 
indicate standard error with 6 repetitions of each condition. *p<0.05 
 
The follow-up in-vitro experiment measuring cellular proliferation had similarly 
encouraging results.  The cells receiving ultrasound treatment (20kHz for 15 minutes at 
100mW/cm2ISPTP) had an average of 35% increased cellular proliferation when compared 
to the control cells, a statistically significant increase(p<0.01).  
6.4 Discussion 
The outcome of the human study described provides valuable insight into the 
possibility of using ultrasound energy in chronic wound management. The in-vitro results 
show that there may be a dose response (here defined as an optimal combination of 
frequency, PRF, and intensity resulting in various amounts of total energy, in Joules(J), 
or energy density, in J/cm2) which is worth further investigation in future studies.  Larger 
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doses (i.e. those received by the 200mW/cm2ISPTPin-vitro group) did not show 
improvements in proliferation or metabolic activity compared to the lower (633J) 
treatment doses.  These findings seem to be supported by those reported by[189], whose 
review paper explores previously reported efficacy of different frequencies (45kHz-
3MHz) and doses (2-150 J/cm2) and suggests that different exposure parameters may 
require unique energy densities or doses to reach therapeutic efficacy. 
 The fact that the wounds exposed to ultrasound showed statistically improved rate 
of wound closure (as was also observed in a prior pilot study of 20 patients exposed to 
several different treatment regimen) supports the use of ultrasound to promote wound 
closure.  Low frequency (20 kHz), low intensity (100mW/cm2) ultrasound seems to 
promote healing at a frequency nearly two orders of magnitude and intensity over one 
order of magnitude lower than the typical therapeutic ultrasound.  The improved 
penetration depth and reduced thermal effects of this therapy level (frequency + 
intensity), combined with reduced risk of inertial cavitation result in a safe, portable, and 
potentially life-saving technology. 
 The optical data also proved to be interesting, as no optical technique has 
previously been reported to track healing in venous ulcers.  As mentioned earlier, the 
previously explored DNIRS technique to assess wound healing in diabetic ulcers was not 
possible for venous ulcers, so an alternative approach was desired.  Using the deep 
penetrating and more dynamically sensitive DCS, it was possible to distinguish healing 
and non-healing ulcers with a 91% positive predictive value and 80% negative predictive 
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value (using −1𝐸−9 𝑐𝑚2 𝑠�
𝑤𝑒𝑒𝑘
  as the cutoff, which was determined by receiver-operating 
characteristic curve, shown below in Figure 33). 
 
Figure 33: Receiver operating characteristic (ROC) curves for distinguishing healing 
from non-healing ulcers based on DCS data. 
  The promising in-vitro fibroblast study results indicate that low intensity, 
low frequency ultrasound promotes healing from the cellular level.  The safe levels of 
ultrasound did not cause thermal effects or damage to the fibroblasts during 
insonification.  Increased cellular metabolism and subsequent proliferation play vital 
roles in the wound healing process.  The in-vitro study data also indicated that pulse 
repetition frequency did not play a role in increasing cellular metabolism.  In conclusion, 
the data presented appear to support the notion that low-intensity (100 mW/cm2ISPTP) 
low-frequency (20 kHz) ultrasound accelerates the healing process through increased cell 
proliferation and metabolism determined by in-vitro studies and a faster rate of wound 
closure seen in a preliminary human pilot study.   
80 
Chapter 7: Segmental Arterial Study using DCS 
7.1 Introduction 
  Peripheral Arterial Disease is consequence of atherosclerosis, the general 
term for impaired blood flow through arteries (typically due to plaque accumulation), 
affects at least 10 million Americans [20].It is very often a chronic disease that leads to 
impaired  mobility and quality of life and directly adds $4.4 billion to annual US 
healthcare costs [21].  It is estimated that PAD is under-diagnosed and undertreated for 
16.5 million asymptomatic Americans[190].  Patients with PAD have a greater risk of 
mortality from coronary disease compared with people without PAD. The narrowing or 
blocking of arteries can cause pain in the legs (called intermittent claudication), lead to 
strokes, cause gangrene and loss of limb, or other complications[22]. Approximately 30% 
patients with PAD have a history of tobacco smoking or diabetes.  
Vascular laboratories provide several tests for establishing PAD diagnosis and its 
severity. Ankle-brachial index (ABI) is the most studied and widely-used method for 
assessment of PAD in lower limbs. ABI is the ratio of the systolic blood pressure at the 
ankle (dorsalis pedis and posterior tibial arteries) position to the arm (brachial artery) 
position.  It can be obtained in approximately 15 minutes using an inflatable blood 
pressure cuff and Doppler ultrasound[191].ABI values less than 0.9 indicate that PAD is 
likely; values less than 0.4 indicate severe arterial disease.  One limitation of ABI is that 
it cannot be measured in patients having peripheral arteries that cannot be compressed 
using an inflatable cuff.  This may occur as a result of medial arterial calcification, 
especially in diabetic or elderly patients[191].  Segmental pressure studies can be used to 
identify the location of a stenosis within a limb by placing inflatable cuffs at 4-5 locations 
along the limb and comparing blood pressures at each location.  Segmental pressure 
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studies are often combined with pulse volume recordings (PVRs), which measures 
changes in the volume of a limb during systole.  This is accomplished using a 
pneumoplethysmograph with volume-sensing cuffs placed at various locations along the 
limb[191].  Arterial stenoses cause a reduction of the magnitude of the pulse volume; 
reduced or flattened PVRs are typically assessed qualitatively by clinicians when 
diagnosing PAD.  Although quantitative parameters for using PVR to diagnose PAD 
have not been established, PVR is not affected by noncompressible arteries, which allows 
it to be used with patients for whom ABI cannot be obtained[191].Segmental pressure 
studies combined with PVR are often prescribed for patients with suspected PAD.  These 
tests take approximately 30 minutes and require trained professionals to operate 
equipment and interpret data to diagnose the severity of PAD. Therefore, there is a 
clinical need for a rapid, quantitative assessment of vascular health to determine PAD 
severity as well as the effects of other vascular impairments, specifically cigarette 
smoking.  
As mentioned earlier, cigarette smoking is the most important risk factor for 
development of PAD[35].  Forty-four million Americans smoke tobacco products[192], 
which results in impaired arterial health[33]. It has been well documented that cigarette 
smoking or passive (secondhand) tobacco exposure can lead to endothelial cell 
dysfunction, even 20 years after tobacco exposure stopped[34].  Endothelial cell 
dysfunction results in impairment of blood vessels’ ability to expand during reactive 
hyperemia [34, 37], which is directly related to the research presented here.   
 Previous studies have reported success in using near infrared spectroscopy 
methods  to determine delays in reperfusion following exercise in patients with PAD[193, 
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194]. Both studies used continuous-wave near infrared spectroscopy methods to assess 
relative oxygenation values in the tissue during reactive hyperemia associated with flow 
mediated dilatation (the reperfusion caused by vessel occlusion).  The studies showed 
that the reperfusion time in subjects with PAD was nearly twice as long as in healthy 
subjects.   
In another study by Yu et al., Diffuse Correlation and Reflectance Spectroscopies 
were used to assess the differences in blood flow between healthy subjects and one 
subject with PAD[123].  Relative microcirculatory blood flow was assessed in the calf 
muscles (>5mm depth penetration) of subjects following cuff occlusion and mild 
exercise.  This study also showed a delayed reperfusion time and a suppressed 
reperfusion magnitude following occlusion for the subject with PAD. 
 Diffuse Correlation Spectroscopy has become a recent tool for assessing 
microvascular flow in deep (up to several centimeters) tissues[123, 195]. DCS uses the 
fluctuations in temporal intensity of multiply scattered light to noninvasively quantify the 
movement of scatters in the tissue (predominantly red blood cells) and has been validated 
against other modalities (namely arterial spin labeled MRI and Doppler Ultrasound) [117, 
120, 129, 150].  Similarly, DNIRS noninvasively assesses concentrations of oxy- and 
deoxy-hemoglobin, the two primary absorbers at near infrared wavelengths (typically 
650nm to 850nm[13]) and has been utilized in human studies ranging from transcranial 
blood oxygen saturation measurements[119, 196], to assessing measuring blood flow in 
breast tumors[125], as well as prediction of wound healing by the author’s research 
group[17, 18, 155, 177].   These two technologies were combined and used to assess 
PAD severity and the vascular effects of cigarette smoking in this pilot study. 
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7.2 Materials and Methods 7.2.1 Optical Technologies 
 Our experimental setup consists from two parts: diffuse correlation spectroscopy 
(DCS) and Diffuse Near Infrared spectroscopy (DNIS), both of which are described 
earlier. A schematic of the DCS system, combined with the Diffuse Near Infrared 
Spectroscopy system, used in this study is shown in Figure 34.  To quickly recap the 
device, a multimode optical fiber is used to transport light (wavelength 785nm) from a 
long-coherence (~10m) length laser (CrystaLaser, Reno, NV) to the tissue.  A bundle of 4 
single mode fibers (core diameter ~5µm), located 1.1cm from the multimode fiber, 
transports light from the tissue to a single photon counting module (SPCM) (Pacer, Palm 
Beach Gardens, FL). The penetration depth is approximately 5mm into the tissue, based 
Figure 34: Block Diagram of Diffuse Near Infrared and Correlation Spectroscopy Systems 
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upon the general rule that depth penetration in tissue is between 1/3 and 1/2 of the source-
detector separation[197, 198].  Single-mode fibers are used for detection because they 
can detect intensity fluctuations in a single speckle area.  The output of the SPCM is 
connected to a multi-tau autocorrelator (Correlator.com, Shen Zhen, China).  The 
autocorrelator converts the photon arrival times into the temporal autocorrelation function 
of scattered light intensity,𝑔2(𝜏) = <𝐼(𝑡)𝐼(𝑡+𝜏)><𝐼(𝑡)𝐼(𝑡)> , where Iis the registered light intensity at 
time t, τ is the delay time of the correlator, and <> is used to denote averaging, which is 
performed throughout the entire acquisition time. A complete description of how the 
autocorrelator operates can be found in [199].   
To calculate the flow (DB) from g2, the knowledge of the tissue's optical scattering 
and absorption coefficients is required.  These properties can be measured in the same 
tissue volume as DCS measurements using Diffuse Near Infrared Spectroscopy (DNIRS), 
described previously [17, 18, 155, 177] and shown in Figure 34. Briefly, the frequency-
domain DNIRS system used here is comprised of six source fibers (see Figure 34) which 
deliver 70 MHz intensity-modulated light from laser-diodes at 685nm or 830nm 
wavelengths to the tissue. The light passes through a MEMs optical switch which allows 
the transmission of one wavelength of light at a time through one source fiber at a time.  
The backscattered light is collected by two detector fibers located in the experimental 
probe between 4-16mm from the various source fibers and is registered by avalanche 
photodiodes.  The device then uses a quadrature demodulator to measure shifts in phase 
and changing amplitude in the scattered light compared to incident light, both as a 
function of source-detector separations.  These data are fit to the diffusion approximation 
model and the optical absorption (µa) and reduced optical scattering (µs') coefficients are 
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calculated[200]. The optical scattering and absorption coefficients can be used to then 
calculate the oxygen saturation and hemoglobin concentrations of the capillary beds in 
the measured tissue. The two systems are integrated such that all optical fibers connect to 
a single (PTFE) Teflon probe, shown in Figure 7.  It should be noted that the DNIRS 
system does not have a 785nm wavelength laser, so the optical absorption and scattering 
coefficients are estimated using the 685nm and 830nm coefficients calculated by the 
DNIRS. 
Both devices connect to a single laptop computer which alternates data collection 
between the DCS and DNIRS.  During DCS 
measurements, the all DNIRS system laser sources are 
turned off, ensuring the light does not affect the 
autocorrelation function.  The DCS source light 
remains on throughout the measurement cycle, 
however since the light is not modulated, it does not 
impact the DNIRS measurements (verified during 
preliminary testing, less than 2% variation and DNIRS 
detectors remained in their linear range of detection).  
At each individual measurement time point, the DCS device collected a single blood flow 
index with an averaging time of 1.5 seconds.  Following this, the DNIRS device 
completed a single measurement (involving the scanning 2 separate wavelengths through 
6 optical fibers).  The DNIRS measurement took ~2.5 seconds.   The overall system flow 
diagram is shown in Figure 35.  
Figure 35: DNIRS/DCS flow 
diagram 
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Twelve patients with symptoms of PAD (typically intermittent claudication) who were 
prescribed a segmental arterial study with pulse volume recording were recruited from 
the Drexel University Department of Surgery Vascular Laboratory.  The study protocol 
was reviewed and approved by the Drexel University College of Medicine Institutional 
Review Board.  Eligible patients were between the ages of 18 and 80 and had no known 
acute deep vein thromboses.  Patients underwent a routine segmental study, administered 
by a skilled ultrasound technologist and as prescribed by the treating physician.  
For the optical study, 
immediately after 
completing the segmental 
arterial study which was 
administered by a skilled 
ultrasound technologist, a 
blood pressure cuff was 
placed on the calf of each 
patient’s symptomatic leg.  
This location was chosen as 
it was far enough away from 
the optical probe to not cause 
motion artifacts, yet was not too far up the leg to cause discomfort (the thighs required 
higher pressures (>200mmHg) to occlude the arteries).The optical probe was placed on 
the ball of the foot and secured with silk medical tape.  Baseline blood flow 
measurements were taken for 2 minutes (~4 second temporal resolution, shown in Figure 
Figure 36: Model of blood flow indices over time 
during compression and following release. A represents 
the delay between cuff release and the first reperfusion 
spike while B represents the ratio of the maximum 
amplitude of blood flow following cuff release to the 
baseline blood flow. 
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35), then the cuff was inflated to 25mmHg higher than the ultrasound-determined systolic 
pressure. The cuff remained inflated for approximately 4 minutes while continuous 
optical measurements (DNIRS and DCS) were taken after which the pressure was 
released and the blood flow (i.e. measured diffusion coefficient) was monitored for an 
additional 2 minutes.  A model of the expected blood flow indices at each phase of the 
experiment is shown in Figure 36. 
The optical absorption and reduced scattering coefficients (µa and µs’) and blood 
flow index (BFI) at each time point was calculated and specific markers of disease were 
quantified, including the delay before a reperfusion spike occurred (see A in Figure 36) 
and the magnitude of the highest post-
release flow recorded (relative to the 
patient's baseline flow, see B in Figure 
36).  Data values were collected using a 
lab-designed LabView (National 
Instruments, Austin, TX) software 
interface and analyzed using MATLAB 
(MathWorks Inc., Natick, MA) software.  
The patient diagnoses (as determined by 
the physician based on the results of the segmental arterial study with pulse volume 
recording and patient history), and brief vascular medical history (including tobacco use, 
diabetes status, and use of high blood pressure or cholesterol medications), were gathered 
and then compared to the calculated optical values and time points mentioned above.  
Mild PAD was determined based upon an ABI between 0.9 and 0.7 as well as a biphasic 
Figure 37: Typical experimental autocorrelation 
curves during baseline, compression, and 
following release.  The solid lines represent raw 
data whereas the dashed lines represent the best 
fit using Equation 3. 
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PVR, whereas moderate to severe PAD represented patients with ABIs below 0.7 and 
either blunted biphasic or flat line PVRs. Student’s T-tests were used as they are the 
typical statistical test for determining differences between two groups, in this case, those 
patients with and without PAD as well as smokers and non-smokers. 
7.3 Results 
Figure 38: Example of collected BFIs over time during compression protocol.  The 
diamonds represent a non-smoking patient without PAD, the triangles represent a 
non-smoker with moderate PAD, and the squares represent a patient with mild 
PAD who smokes.   Each plot was normalized to the patient’s average baseline 
blood flow (100%) and the lines represent a 3-point moving average. 
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 A set of typical experimental autocorrelation 
curves is shown in Figure 37.  The data show that when the blood flow is compressed, the 
autocorrelation curve shifts to the right (representing an increased correlation time and 
consequently slower blood flow), and following release, where blood flow is fastest (see 
maximum value of Figure 36), the curve shifts to the left (decreased correlation time) and 
exhibits more rapid exponential decay compared to baseline, as expected[201]. As the 
BFI is predominantly dependent upon the scattering coefficient, a small error in µs’ can 
lead to large changes in the BFI, exemplified by Figure 39.  In this figure, BFIs were 
calculated using Equation 5 and it can be seen that doubling the absorption coefficient 
(µa) minimally affects (<10%) the BFI whereas doubling the scattering coefficient (µs’) 
changes the BFI by nearly 400%.  As the DNIRS and DCS systems alternated, marginal 
variations in the tissue conditions from one second to the next caused errors in the 
calculated blood flow indices.  These errors, combined with motion artifacts, manifested 
as the noticeable noise during the experiment, seen in Figure 38. Prior to analysis, noise 
Figure 39: 3D plot of BFI obtained 
following changes in absorption and 
scattering coefficients 
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in the raw data was reduced by taking the moving 3 point average of all data points 
(represented as the solid and dashed lines for the three patients).  
Of the 12 patients enrolled in the study, three were diagnosed by segmental 
arterial study with PVR as having no PAD, five had mild PAD, two had moderate PAD, 
and two had severe PAD.  Clinical 
diagnoses of all patients can be found in 
Table 1. 
It was hypothesized that PAD 
severity would link to the delay in 
reperfusion (represented as “A” in Figure 
36) following cuff release.  As shown in 
Figure 40: Time delay to reperfusion spike 
based upon Peripheral Arterial Disease 
severity.  Bars represent standard error. 
*p<0.02 
Table 3: PVR/Segmental Diagnosis and Optical Data Points by smoking history 
91 
Figure 40, this trend was evident, with a statistical difference (p<0.02) between the 
patients with moderate/severe PAD and healthy patients.    It seems logical that PAD 
severity would cause the impairment (temporal delay) in the process to deliver 
oxygenated blood to tissue with a sudden high oxygen demand.  This would correlate 
with intermittent claudication, the pain experienced by patients with PAD during walking 
or mild exercise[22]. 
 In assessing the medical history 
of the patients, it was discovered that 
cigarette smoking history was 
associated with reduced magnitude of 
the reperfusion spike (parameter B in 
Fig 7).  A comparison of smoking and 
non-smoking reperfusion spike 
magnitudes as a relative percent of the 
patient’s baseline blood flow, is shown in Figure 42. It can be seen that the average 
currently non-smoking patient had a reperfusion spike of greater than 400% of their 
Figure 42: Capillary reperfusion spike 
magnitude relative to average baseline flow 
by tobacco use.** p<0.02. (B) All bars 
represent standard error. 
Figure 41: (A) Capillary oxygen saturation based on tobacco use. (B)Hemoglobin 
concentrations of smokers and non-smokers. Error bars represent standard error. 
**p<0.02, *p<0.05 
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baseline flow, whereas current smokers had a spike of less than 200% (p<0.02).  Of the 
non-smokers, those who were former smokers (n=3) averaged a spike of 290%, compared 
to 510% for those who never smoked (n=4), showing a correlation between tobacco use 
and an impaired reperfusion spike.  
 A second interesting difference between smokers and non-smokers involved the 
oxygen saturation, as assessed with the DNIRS optical system.  As seen in Figure 41A, 
smokers had statistically (p<0.02) greater oxygen saturation than non-smokers. It was 
further determined that smokers and non-smokers had similar quantities of deoxygenated 
hemoglobin, but smokers had nearly twice as much oxygenated hemoglobin (shown in 
Figure 41B).   
7.4 Conclusions/Discussion: 
 Several hemodynamic abnormalities in subjects with PAD or smokers were 
documented during this study.  First, endothelial health was assessed by monitoring 
reperfusion rates and magnitudes following an induced ischemic event. Previous studies 
have found that peripheral arterial disease is associated with impaired flow mediated 
dilation, specifically  delayed reperfusion[193, 194].  The delayed reperfusion spike seen 
in patients with PAD also matches the results presented using similar optical techniques, 
albeit with a single patient in the PAD group[123]. However, it has been previously 
reported [113, 123, 194] that PAD also causes a reduction in the magnitude of the 
reperfusion spike.  In the data collected here, this was not found to be true.  Patients with 
and without PAD had statistically similar reperfusion spikes as a percent of baseline 
value, peaking at 310% for patients without PAD and 320% for those with PAD. 
Smoking, rather than PAD, seemed to be the only direct cause of impairment in the 
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reperfusion spike magnitude (relative to baseline).  To confirm this, reperfusion 
magnitudes were separated into patients without PAD who do not smoke (310%±SEM), 
patients with PAD who did not smoke (490%±SEM), and patients with PAD who did 
smoke (190%±SEM).  While the difference between non-smokers with and without PAD 
was not significant (p>0.10), the difference between patients with PAD who did and did 
not smoke was significant (p<0.01).  This means that previous reports [113, 123, 194] 
conflating impaired reperfusion spike magnitudes with PAD may have ignored the 
impact of tobacco use on the values, which can be difficult to control for, as smoking and 
PAD often coincide.  To understand why reperfusion magnitudes were higher in non-
smoking patients with PAD than non-smoking patients without PAD (310% vs. 490%), it 
seems logical that the impaired endothelial function which delays vasodilation of the 
vessels causes the velocity within the vessels to compensate.  This means that the blood 
would need to move faster through the narrow vessel to exchange the same blood volume 
as slower moving blood in a dilated vessel.  This would account for the higher 
reperfusion magnitudes seen in non-smoking patients with PAD compared to healthy 
patients, since BFI is proportional to average velocity of blood flow within the scanned 
tissue volume. 
 The data in Figure 42show that tobacco use results in reduced arterial compliance, 
limiting the ability of the vessels to dilate when there is a sudden oxygen demand. Studies 
have previously shown that smoking can cause an impaired reperfusion, as assessed using 
ultrasound to measure arterial diameter following compression [33, 202]. These results 
(Figure 41) further indicate that smokers have impairment in the process of delivery 
oxygen to the tissue in the capillaries.  This is corroborated by previous reports from 
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literature which show that smoking causes an increase in red blood cell count [39] and 
results in blood cells with a higher oxygen affinity (impairing the ability to release 
oxygen when needed)[38].  It is worthy of notice that carboxyhemoglobin (hemoglobin 
with bound carbon monoxide and a known biological product of smoking) does not 
absorb light at the same wavelength as oxygenated hemoglobin (absorption at 785nm is 
an order of magnitude lower for carboxyhemoglobin than oxygenated hemoglobin)[203], 
ensuring that the chromophore being assessed (in Figure 41) was indeed oxy-hemoglobin. 
 Finally it should be noted that every patient enrolled in this study had complaints 
of intermittent claudication, meaning that no patients were completely “healthy.”  
Therefore, this study represents a clinically-relevant screening tool for significantly 
(p<0.02) differentiating patients without PAD from those with moderate to severe PAD.   
It should also be noted that since the protocol here took less than 10 minutes to 
implement, this represents a faster assessment to assess PAD severity when compared to 
a full pulse-volume recording and segmental arterial study in a vascular laboratory. 
The results reported here validate the use of a novel technique (flow-mediated 
dilatation assessment by Diffuse Correlation and Near Infrared Spectroscopies) to study 
arterial compliance in patients with impaired endothelial function, specifically relating to 
peripheral arterial disease severity and tobacco use.  While not intended to replace the 
current golden standard ankle-brachial index for arterial health, this method could 
provide supplemental information which may have been overlooked using subjective 
methodologies or provide a rapid (<10 minute) screening technique which can be 
performed by non-medical experts.   
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Chapter 8: Conclusions and Future work 
 
 Diffuse Correlation Spectroscopy (DCS) and Diffuse Near Infrared Spectroscopy 
(DNIRS), two noninvasive methods of assessing changes in vasculature, were used to 
determine progression and healing as it related to venous and arterial diseases.  The two 
approaches can either work independently or together to provide static and dynamic 
information related to changes in tissue oxygenation or blood flow over time.  These 
changes may be week to week (as seen in the diabetic and venous ulcer studies) or within 
a single measurement session, performed after vessel constriction (as seen in the 
segmental arterial study of PAD and smoking effects).  The purpose of this research was 
to validate these new technology systems as methods to quantitatively categorize vascular 
disease and provide an alternative to the current clinical standard assessment techniques.  
Both diabetic and venous ulcers were evaluated using DNIRS and DCS techniques, 
respectively.  Effects of PAD and tobacco on flow-mediated dilation/capillary 
reperfusion were examined using the DCS device. 
 The results of the diabetic foot ulcer study indicated that the investigatory optical 
system was able to detect the differences in concentration of oxygenated hemoglobin at 
the injury site compared to the healthy, non-ulcerated tissue.  By taking measurements at 
the same location weekly, it was possible to detect a decrease in oxygenated hemoglobin 
over time in healing ulcers.  Not only was this method able to predict healing in 4 weeks 
(p<0.01), but it also yielded positive and negative predictive values which were superior 
to wound size measurements (82% and 92% vs. 62% and 91%), the current gold standard 
wound assessment technique. Were this technique used in a clinical setting, it would 
permit the therapy to be adjusted in case the 4 week optical marker indicated non-healing, 
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and potentially save over $12,000 per patient.  While studies with larger patient cohorts 
are needed to further validate these figures, the results of this study appear to suggest that 
Diffuse Near Infrared Spectroscopy is an effective predictor of diabetic ulcer healing. 
 The second study evaluated the use of a novel ultrasound therapy to treat venous 
ulcers. Diffuse Correlation Spectroscopy (combined with the DNIRS technology) was 
used to monitor capillary flow over time, which, much like the hemoglobin concentration 
from the diabetic ulcer study, trended downward towards baseline flow rates in healing 
ulcers.  Over time, healing ulcers showed a statistically significant decrease in this flow 
compared to non-healing ulcers (p<0.01).  This technique was also able to determine that 
wounds treated with ultrasound showed a reduction in flow whereas the untreated ulcers 
did not (p<0.01).  It is also noteworthy that this technique was more statistically 
significant than wound size changes (p<0.04), which indicates that, similarly to the 
diabetic ulcer study, optical spectroscopy may provide additional sensitivity than wound 
size measurements alone.  This must be validated with a larger patient population to truly 
determine the sensitivity and specificity of using DCS to predict healing in venous ulcers; 
the above preliminary conclusions are based on the results of a limited 16 patient pilot 
study. 
 With respect to the segmental arterial study, it should be reiterated that 12 patients 
were assessed using DCS in a pilot study to determine if any correlation existed between 
the capillary reperfusion profile and documented diseases of the peripheral arterial 
system.  The study revealed that certain markers in the reperfusion process (time to peak 
and magnitude) were associated with PAD severity and tobacco use.  A delay in the spike 
following pressure release was directly correlated with increasing peripheral arterial 
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disease severity, as determined by a gold-standard segmental arterial study, whereas a 
suppressed or non-existent spike was associated with smoking (p<0.02).  These results 
challenge the previous assertion that PAD results in both a delayed and impaired 
reperfusion spike, when in fact a reduced reperfusion magnitude (peak relative blood 
flow following cuff occlusion) was only attributable to smoking history. This small 
feasibility study indicates that flow mediated dilatation as measured with DCS may be 
preferable to the use of diagnostic Doppler ultrasound to measure arterial diameters.  
 Future work with the DNIRS/DCS systems may include: (1) the assessment of 
venous ulcers using the combined optical systems in a larger (statistically powerful) 
sample size (n=50) to further validate the prediction method.  The pilot human study 
described here was limited to 16 patients and focused on the therapy, not the predictive 
capacity of the optical device.  A separate human study with the sole purpose of using 
DCS to predict healing in venous ulcers (at shorter 4-week time points as well as 12-
week) should be performed, allowing the determination of a particular therapy’s efficacy 
in a short, 4-week time frame.  (2) The future work should also explore the use of DCS to 
assess other tissue damage models, specifically pressure ulcer formation.  The unique 
ability of the DCS system to assess microcirculatory flow at depths up to 1cm would 
allow the observation of restricted flow in high-risk areas of a patient.  (3) Future work 
should use the DCS/DNIRS systems to predict future cardiovascular events, as this could 
provide a novel screening tool to supplement/replace the ionizing cardiac stress test.  This 
is because flow mediated dilatation following arterial occlusion is a useful predictor of 
future cardiovascular events[204]. The results of this study, and those reported in [123], 
corroborate that DNIRS and DCS could be used to assess flow mediated dilatation with 
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greater sensitivity than diagnostic ultrasound techniques, specifically due to the vessel 
diameters of interest[205]).  Hence it would appear that this technique would provide a 
non-ionizing, alternative screening tool for patients with angina, chest pain, known 
coronary heart disease, or other indication for a nuclear cardiac stress test[206]. 
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